Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance

Weihua Zhou and Daniel R. Wahl *

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
* Correspondence: dwahl@med.umich.edu; Tel.: +1-734-936-4300; Fax: +1-734-763-7371

Received: 19 June 2019; Accepted: 16 August 2019; Published: 23 August 2019

Abstract: Glioblastoma (GBM) is the most common and aggressive primary brain tumor and is nearly universally fatal. Targeted therapy and immunotherapy have had limited success in GBM, leaving surgery, alkylating chemotherapy and ionizing radiation as the standards of care. Like most cancers, GBMs rewire metabolism to fuel survival, proliferation, and invasion. Emerging evidence suggests that this metabolic reprogramming also mediates resistance to the standard-of-care therapies used to treat GBM. In this review, we discuss the noteworthy metabolic features of GBM, the key pathways that reshape tumor metabolism, and how inhibiting abnormal metabolism may be able to overcome the inherent resistance of GBM to radiation and chemotherapy.

Keywords: glioma; glioblastoma; metabolism; metabolic remodeling; metabolic targeting; radiation

1. Introduction

Glioblastoma (GBM) is the most prevalent and lethal primary brain tumors in adults, with a median overall survival of approximately 15 months [1–3]. Standard therapy for GBM consists of maximal surgical resection, followed by radiotherapy and concurrent and adjuvant temozolomide (TMZ; an orally available alkylating chemotherapy) [4,5]. Despite this multimodality treatment, GBMs inevitably recur. Recurrences are typically local (i.e., within the high dose radiation field) and extracranial metastases are extraordinarily rare [6].

Therapeutic options are limited following recurrence and include re-resection, re-irradiation, additional cytotoxic chemotherapy, and bevacizumab, a humanized vascular endothelial growth factor monoclonal antibody that inhibits angiogenesis [7]. Upon recurrence, the average survival time for a patient with GBM is approximately six months, which reemphasizes the need to develop novel therapeutic approaches [8].

The search for new therapies for GBM has largely centered on the molecular targets uncovered through large-scale genomic analysis efforts such as The Cancer Genome Atlas. Most GBMs harbor recurrent molecular alterations disrupting core pathways involved in regulation of growth (EGFR [9,10], PDGFRα [11], FGFR [12,13], mitogen-activated protein kinase (MAPK) [14,15] and phosphoinositide 3-kinase (PI3K) [16,17] signaling pathways), cell cycle [18–21], autophagy [22], DNA repair, and apoptosis [23,24], as well as regulators of angiogenesis [25,26] and immune checkpoints [27–29]. Unfortunately, personalized therapies targeting these genomic alterations have not yet been successful in the clinic, possibly due to the intense intratumoral heterogeneity that characterizes GBM [30]. New treatment strategies that may be efficacious despite intratumoral genomic heterogeneity are urgently needed.

Altered cellular metabolism is a hallmark of cancer. Like most cancers, GBMs rewire metabolism for numerous pro-growth and -survival functions including macromolecule synthesis, ATP generation...
and antioxidant regeneration. Distinct oncogenic alterations (e.g., MYC amplification, PTEN deletion, and TP53 mutation) can activate common metabolic adaptations such as increased glycolytic activity and lead to tumor cell growth or progression [31]. Since many of the metabolic adaptations of GBM can exist across numerous genotypes, it is possible that a therapeutic strategy of targeting abnormal metabolism may meet more success than targeting genomic alterations in a heterogeneous tumor such as GBM. Hence, GBM metabolism is an area of intense research to identify novel therapeutic targets and biomarkers [32]. In this review, we firstly review the updated molecular classification of glioma and GBM, discuss the metabolic features of GBMs, and highlight how specific metabolic processes regulate tumorigenesis and progression in GBM. Finally, we will discuss how targeting abnormal GBM metabolisms may overcome resistance to standard therapies.

2. Histopathologic and Molecular Classification of Diffuse Gliomas

Diffuse gliomas are the most frequent primary adult malignant brain tumors and have historically been diagnosed based on their histologic resemblance to astrocytes or oligodendrocytes using conventional microscopy [33,34]. In 2016, the World Health Organization (WHO) revised their classification system of diffuse gliomas to account for definitional molecular alterations including mutations in isocitrate dehydrogenase (IDH) and whole-arm deletions of the chromosomal arms 1p and 19 q (termed 1p/19q codeletion) [34,35] (Figure 1). Oligodendrogliomas are now defined as having both mutations of IDH and codeletion of 1p/19q. Oligodendrogliomas are low grade (WHO grade 2) if they have little morphologic atypia under conventional microscopy and anaplastic (WHO grade 3) if they have aggressive morphologic features such as increased mitotic activity, microvascular proliferation, or necrosis. When treated with combined radiation and chemotherapy, patients with grade 2 or 3 oligodendrogliomas have favorable survival times (median >10 years) [36,37]. IDH-mutant astrocytomas are defined by the presence of an IDH mutation and the absence of 1p/19q codeletion. These tumors also frequently harbor mutations in p53 and ATRX, though these alterations are not definitional. Patients with IDH mutant astrocytomas that are grade 2 (termed low grade or diffuse) or grade 3 (termed anaplastic, based on the presence of increased mitotic activity) and receiving optimal therapy have a median overall survival on the order of 8–12 years depending on the study [38]. Grade 2 and grade 3 IDH-mutant astrocytomas often develop more aggressive behavior, which is accompanied by microscopic features such as necrosis and microvascular proliferation and additional molecular changes such as CDKN2A/B loss. These changes are characteristic of an IDH mutant GBM (IDHmutGBM), which are often termed “secondary” GBM due to their transformation from lower grade tumors. Patients with IDHmutGBM have median survival times between two and three years [39,40]. Diffuse astrocytomas without IDH mutations are aggressive tumors that often contain EGFR amplification, TERT promoter mutation, and/or aneuploidy in chromosomes 7 and 10. When IDH-wild type diffuse gliomas have aggressive histologic features such as necrosis and microvascular proliferation they are termed GBM (WHO grade 4). These IDHwtGBM account for more than 90% of all GBM and, unlike IDHmutGBM, arise de novo and have short natural histories. The median survival time for patients with IDHwtGBM is on the order of 1–1.5 years [4,39]. Patients with diffuse astrocytomas that lack the IDH mutation but whose tumors lack the histologic criteria to be called GBM have natural histories that more closely resemble IDHwtGBM than their grade 2 or 3 IDH-mutant counterparts [41]. Like their natural history and etiology, the metabolic characteristics and liabilities of GBM with and without IDH mutations are distinct and described separately below. A recently described discrete type of high grade glioma (the H3K27 mutant diffuse midline glioma) is definitionally grade 4 based on its molecular rather than histologic features, but its associated metabolic abnormalities fall outside the scope of this review [42].
Figure 1. Classification of diffuse gliomas. As of 2016, diffuse gliomas are now defined based on both their molecular and histologic features. Definitional molecular features are noted in red, while other common molecular features are also listed. For most diffuse gliomas, the grade is still determined by the presence of conventionally defined “aggressive” microscopic features such as atypia, mitoses, microvascular proliferation, and necrosis. H3K27 mutant midline gliomas are grade 4 based on their molecular features. Median survival estimates for each type of molecularly defined tumor receiving optimal therapy are listed in green, though many of these estimates should be viewed as preliminary due to the recent reclassification of these tumors [4,33–42].

3. Metabolic Characteristics of IDHwtGBM

3.1. Glycolysis

Glycolysis is responsible for catabolizing glucose to pyruvate, which can be converted to lactate and secreted or enter the TCA cycle via either pyruvate dehydrogenase (to generate NADH and ATP) or pyruvate carboxylase (to contribute to anaplerosis, Figure 2). GBM is associated with a significant increase in glycolysis for energy production [43]. Hexokinase (HK) catalyzes the first glycolytic step to generate glucose-6-phosphate, with the isoform HK2 strongly expressing in cancers including GBM [44]. ENO1, an isoform of the glycolytic gene enolase generating phosphoenolpyruvate (PEP), is deleted in GBM, and ENO2 silencing selectively inhibits growth, survival and tumorigenic potential of ENO1-deleted GBM cells [45]. Knockdown of glycolytic genes (HK2, PFKP, ALDOA, PGAM1, ENO1, ENO2, and PDK1) strongly inhibits GBM growth [46], indicating that key glycolytic enzymes are essential for GBM growth.
translocation of PGK1 to the nucleus, which phosphorylates and activates PDHK1. This signaling inhibits PDH activity and promotes GBM tumor development [49]. High-level amplification of MYC and MYCN genes are also observed in GBM [11,50,51], and inhibition of Myc-induced glycolysis selectively killed MYC/MYCN-amplified patient-derived GBM tumor spheres and extended the survival of mice bearing MYCN-amplified PDX [49]. The mechanistic target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) are frequently aberrantly activated in GBM. Intriguingly, mTORC2 regulates glycolytic metabolism in GBM through Akt-independent phosphorylation of class IIa histone deacetylases (HDACs) to release c-Myc [52].

Pyruvate kinase (PK) catalyzes the final step in glycolysis by irreversibly transferring the phosphate group from phosphoenolpyruvate (PEP) to produce pyruvate and ATP. PK consists of four isoforms encoded by two genes, PKLR and PKM. Alternative splicing of PKM pre-mRNA further generates PKM1 and PKM2 isoforms [53]. PKM2, but not PKM1, is selectively expressed in proliferating or tumor cells [54,55]. PKM2 can disassociate HDAC3 from the MYC promoter to promote GBM tumorigenesis through directly binding and phosphorylating histone H3 [56]. EGFR activation in GBM induces translocation of PKM2 into the nucleus to transactivate β-catenin, which mediates the upregulation of c-Myc-dependent glycolysis and cell proliferation [57]. During oxidative stress, the metabolic proteins of glycolysis in IDHwtGBM are frequently regulated by oncogenic signaling pathways. Ras, serving as an upstream pathway, inhibits pyruvate dehydrogenase (PDH) activity through downregulation of PDH phosphatase (PDP) expression and promotes GBM tumorigenesis [47]. AKT binds to and phosphorylates the PFK1 platelet (PFKP) isoform and elevates PFKP expression in GBM, leading to cell proliferation, tumor growth, and poor prognosis [48]. Hypoxia, EGFR, K-Ras-G12V, and B-Raf-V600E can all stimulate glycolysis by inducing the translocation of PGK1 to the nucleus, which phosphorylates and activates PDHK1. This signaling inhibits PDH activity and promotes GBM tumor development [49]. High-level amplification of MYC and MYCN genes are also observed in GBM [11,50,51], and inhibition of Myc-induced glycolysis selectively killed MYC/MYCN-amplified patient-derived GBM tumor spheres and extended the survival of mice bearing MYCN-amplified PDX [49]. The mechanistic target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) are frequently aberrantly activated in GBM. Intriguingly, mTORC2 regulates glycolytic metabolism in GBM through Akt-independent phosphorylation of class IIa histone deacetylases (HDACs) to release c-Myc [52].

Pyruvate kinase (PK) catalyzes the final step in glycolysis by irreversibly transferring the phosphate group from phosphoenolpyruvate (PEP) to produce pyruvate and ATP. PK consists of four isoforms encoded by two genes, PKLR and PKM. Alternative splicing of PKM pre-mRNA further generates PKM1 and PKM2 isoforms [53]. PKM2, but not PKM1, is selectively expressed in proliferating or tumor cells [54,55]. PKM2 can disassociate HDAC3 from the MYC promoter to promote GBM tumorigenesis through directly binding and phosphorylating histone H3 [56]. EGFR activation in GBM induces translocation of PKM2 into the nucleus to transactivate β-catenin, which mediates the upregulation of c-Myc-dependent glycolysis and cell proliferation [57]. During oxidative stress, the metabolic proteins of glycolysis in IDHwtGBM are frequently regulated by oncogenic signaling pathways. Ras, serving as an upstream pathway, inhibits pyruvate dehydrogenase (PDH) activity through downregulation of PDH phosphatase (PDP) expression and promotes GBM tumorigenesis [47]. AKT binds to and phosphorylates the PFK1 platelet (PFKP) isoform and elevates PFKP expression in GBM, leading to cell proliferation, tumor growth, and poor prognosis [48]. Hypoxia, EGFR, K-Ras-G12V, and B-Raf-V600E can all stimulate glycolysis by inducing the translocation of PGK1 to the nucleus, which phosphorylates and activates PDHK1. This signaling inhibits PDH activity and promotes GBM tumor development [49]. High-level amplification of MYC and MYCN genes are also observed in GBM [11,50,51], and inhibition of Myc-induced glycolysis selectively killed MYC/MYCN-amplified patient-derived GBM tumor spheres and extended the survival of mice bearing MYCN-amplified PDX [49]. The mechanistic target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) are frequently aberrantly activated in GBM. Intriguingly, mTORC2 regulates glycolytic metabolism in GBM through Akt-independent phosphorylation of class IIa histone deacetylases (HDACs) to release c-Myc [52].

Pyruvate kinase (PK) catalyzes the final step in glycolysis by irreversibly transferring the phosphate group from phosphoenolpyruvate (PEP) to produce pyruvate and ATP. PK consists of four isoforms encoded by two genes, PKLR and PKM. Alternative splicing of PKM pre-mRNA further generates PKM1 and PKM2 isoforms [53]. PKM2, but not PKM1, is selectively expressed in proliferating or tumor cells [54,55]. PKM2 can disassociate HDAC3 from the MYC promoter to promote GBM tumorigenesis through directly binding and phosphorylating histone H3 [56]. EGFR activation in GBM induces translocation of PKM2 into the nucleus to transactivate β-catenin, which mediates the upregulation of c-Myc-dependent glycolysis and cell proliferation [57]. During oxidative stress, the metabolic proteins of glycolysis in IDHwtGBM are frequently regulated by oncogenic signaling pathways. Ras, serving as an upstream pathway, inhibits pyruvate dehydrogenase (PDH) activity through downregulation of PDH phosphatase (PDP) expression and promotes GBM tumorigenesis [47]. AKT binds to and phosphorylates the PFK1 platelet (PFKP) isoform and elevates PFKP expression in GBM, leading to cell proliferation, tumor growth, and poor prognosis [48]. Hypoxia, EGFR, K-Ras-G12V, and B-Raf-V600E can all stimulate glycolysis by inducing the translocation of PGK1 to the nucleus, which phosphorylates and activates PDHK1. This signaling inhibits PDH activity and promotes GBM tumor development [49]. High-level amplification of MYC and MYCN genes are also observed in GBM [11,50,51], and inhibition of Myc-induced glycolysis selectively killed MYC/MYCN-amplified patient-derived GBM tumor spheres and extended the survival of mice bearing MYCN-amplified PDX [49]. The mechanistic target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) are frequently aberrantly activated in GBM. Intriguingly, mTORC2 regulates glycolytic metabolism in GBM through Akt-independent phosphorylation of class IIa histone deacetylases (HDACs) to release c-Myc [52].

Pyruvate kinase (PK) catalyzes the final step in glycolysis by irreversibly transferring the phosphate group from phosphoenolpyruvate (PEP) to produce pyruvate and ATP. PK consists of four isoforms encoded by two genes, PKLR and PKM. Alternative splicing of PKM pre-mRNA further generates PKM1 and PKM2 isoforms [53]. PKM2, but not PKM1, is selectively expressed in proliferating or tumor cells [54,55]. PKM2 can disassociate HDAC3 from the MYC promoter to promote GBM tumorigenesis through directly binding and phosphorylating histone H3 [56]. EGFR activation in GBM induces translocation of PKM2 into the nucleus to transactivate β-catenin, which mediates the upregulation of c-Myc-dependent glycolysis and cell proliferation [57]. During oxidative stress,
cells [54,55], and can disassociate HDAC3 from the MYC promoter to promote GBM tumorigenesis through directly binding and phosphorylating histone H3 [56]. EGFR activation in GBM induces translocation of PKM2 into the nucleus to transactivate β-catenin, which mediates the upregulation of c-Myc-dependent glycolysis and cell proliferation [57]. During oxidative stress, PKM2 can translocate to the mitochondria and phosphorylate Bcl2 to inhibit apoptosis directly, promoting GBM cell growth and correlating with poor prognosis [58]. However, the ability of PKM2 to act as a kinase has recently come into question [59], which makes it possible that its oncogenic properties may be due to its metabolic function. Glycolysis can also be regulated by macrophages, which enhanced PDPK1-mediated phosphorylation of PGK1 by secreting interleukin-6 (IL-6), leading to enhanced glycolysis and GBM tumorigenesis [60].

The high utilization of glucose to support GBM growth and survival indicates that inhibiting glycolysis in GBM may have a therapeutic value. Depletion of HK in intracranial xenograft models of IDHwtGBM decreased tumor proliferation and angiogenesis, but increased invasion [61], and the latter may impact the therapeutic suitability of targeting this pathway. Tumors expressing HK2 may also express HK1, rendering them resistant to HK2 inhibition. Moreover, other metabolically active tissues, including skeletal muscle, cardiac, and adipose tissues, also express HK2 [62], indicating that the anti-tumor effects of HK2 inhibition may be challenged or limited by non-specificity and systemic toxicity. However, systemic knockout of HK2 in mice bearing lung cancer has shown profound therapeutic effects on tumor metabolism and growth, with minimal adverse effects to normal mouse physiology [63]. Additionally, the glucose analog, 2-deoxyglucose (2DG), an inhibitor of the glycolytic pathway, has been tolerated reasonably well in early clinical trials for patients with cancer [64,65]. Thus, despite the dependence of normal brain on glucose, there may be a therapeutic window for targeting glycolytic metabolism in GBM [66].

3.2. TCA Cycle and Acetate

The tricarboxylic acid (TCA) cycle, also known as citric acid or the Krebs cycle, is a central metabolic hub that provides energetic intermediates and/or anabolic precursors through oxidization of acetyl-CoA into carbon dioxide. Both activated oncogenes and deleted tumor suppressors dysregulate the TCA cycle across cancers, making it a possible therapeutic target [67].

In GBM, the major carbon sources for the TCA cycle appear to be glucose and acetate. This mirrors the normal brain, where glucose has long been considered the dominant TCA carbon source, but where other metabolites, such as fatty acids (octanoate), acetate, and ketones, can be used as alternate fuels, especially during hypoglycemia [68,69]. These alternative energy fuels can also drive GBM growth and survival. Indeed, less than 50% of the GBM acetyl-CoA pool is derived from glucose in vivo [70]. Further study in intracranial GBM xenografts showed that acetate contributes a significant fraction of carbon to the TCA cycle in GBMs through the action of acetyl-CoA synthetase enzyme 2 [71]. In contrast to glucose and acetate, circulating glutamine appears to contribute little carbon to the GBM TCA cycle. Rather, many GBMs express glutamine synthetase and utilize astrocyte-derived glutamate to generate the glutamine needed for cellular function [71,72].

Recently, lactate has been reported as an important TCA cycle carbon source in normal tissues and cancers such as non-small cell lung cancer (NSCLC) [73]. The brain appears to behave differently and incorporates little circulating lactate-derived carbon into the TCA cycle [74]. Whether GBM utilizes circulating lactate as a fuel source, or if a separate intracranial pool of lactate exists that can fuel the tumor or normal brain are unanswered questions.

Isocitrate dehydrogenases (IDHs) are a group of enzymes playing a crucial role in the TCA cycle by catalyzing the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), using nicotinamide adenine dinucleotide phosphate (NADP+) or nicotinamide adenine dinucleotide (NAD+) as a cofactor to generate NADPH or NADH during catalysis (Figure 2). Three different IDH paralogs (IDH1, IDH2, and IDH3) have been identified, with IDH1 performing its function in the cytosol and peroxisomes, whereas IDH2 and IDH3 function in the mitochondria [75,76]. IDH1 and IDH2 play important roles in
many cellular functions, including glucose sensing [77], lipogenesis [78,79], glutamine catabolism [78], and cellular defense against reactive oxygen species and radiation [80,81].

IDHwtGBMs upregulate wtIDH1, which fuels tumor growth and therapy resistance. Knockdown of wtIDH1 in IDHwtGBM cell line models depletes NADPH, deoxynucleotides, and antioxidants and makes these models more sensitive to radiotherapy [82]. A complementary study confirmed that wtIDH1 plays an important role in maintaining IDHwtGBM antioxidant levels and drives lipid biosynthesis in these models. This study showed that pharmacologic or genetic inhibition of wtIDH1 increased the sensitivity of these model systems to targeted therapy [83]. Together, these studies suggest that the therapeutic targeting of wtIDH1 may be a promising therapeutic strategy in IDHwtGBM.

3.3. Glutamine Metabolism

Glutamine circulates at high concentrations (~500 µM) and is a carbon and nitrogen source to support biosynthesis, energetics, and cellular homeostasis for cancer cell growth [84]. The total concentration of glutamine is greater in GBM tissue than the surrounding normal brain [43] and the ability to metabolize this glutamine is critical for GBM proliferation and survival [85]. Somewhat surprisingly, circulating glutamine appears to be a minor contributor to the intracranial glutamine pool [86]. Rather than coming from the circulation, brain glutamine is primarily synthesized from glutamate and ammonia in situ by glial cells expressing glutamine synthetase (GS) (Figure 2) [87]. GS expression and function appears important for GBM growth and survival. Patients who GBMs express low or absent levels of GS have approximately two-fold longer survival compared to patients whose tumors express high levels of GS [88]. GS expression is further elevated in the stem-like cells thought to drive GBM recurrence and treatment resistance [89]. The glutamine generated from astrocytes or GS-positive GBM cells supports tumor nucleotide biosynthesis and growth, suggesting that its inhibition may have therapeutic effects.

Glutamine breakdown may also be important for GBM growth and survival. Glutaminase (GLS), which converts glutamine to an ammonium ion and glutamate (Figure 2), is encoded by kidney-type glutaminase (GLS1) and liver-type glutaminase (GLS2) [90]. GLS has been proposed as a therapeutic target in many cancers and clinical trials of glutaminase inhibitors are ongoing, including for patients with GBM (NCT03875313). Targeting GLS slows the growth of subsets of GBMs in vitro and in vivo [91]. The molecular underpinnings of GLS dependence in GBM are under investigation. Models resembling the mesenchymal GBM subtype may be especially sensitive to GLS inhibition [92] as are GBMs that express mutant IDH [93] or that have hyperactive c-Myc [94]. GLS may also play a role in mediating GBM therapy resistance. Elevated GLS and glutamate levels following mTOR inhibition are responsible for the resistance of GBM cells to this compound, and dual inhibition of mTOR and GLS synergistically slows GBM growth in vivo [85].

Together, these studies suggest that targeting glutamine metabolism may have a therapeutic utility for patients with GBM. Particular molecular features such as c-Myc amplification or the mesenchymal transcriptional subtype may be most benefited by this strategy. Patients whose tumors carry the IDH mutation are also excellent candidates for inhibition of glutamine metabolism, and this concept is discussed in more detail in the IDH mutations subsection. Since cortical glutamine levels are generated in situ, it appears that small molecule inhibitors of glutaminase or glutamine uptake may be more effective than dietary modifications to alter circulating glutamine levels [86,89].

3.4. Lipid Metabolism

Lipids are a class of fat-soluble organic compounds that have important structural, signaling and energetic functions in many cancers including GBM. Common lipid types include fatty acids, triglycerides (a glycerol molecule annealed to three fatty acids), phospholipids (a glycerol molecule annealed to two fatty acids and one polar phosphate-containing head group), and cholesterol. GBMs exist in a lipid-rich environment, as the dry weight of normal human brain contains more than 50% lipid and the brain itself contains about a quarter of the body’s cholesterol [95]. Since much of this lipid
is housed in structural elements of normal neural tissue such as myelin, the amount of environmental lipid available to a GBM may be relatively low. Indeed, increasing evidence suggests that GBMs must synthesize significant amounts of lipids to generate the necessary membrane components and lipid signaling molecules needed to proliferate [96].

To synthesize fatty acids (the main component of most lipids) de novo, GBMs must first generate cytosolic acetyl-CoA, which can be formed from citrate via the action of ATP citrate lyase, or from acetate via the action of acetyl-CoA synthetase (ACSS; Figure 2) [97]. The generation of cytosolic acetyl-CoA in GBM is regulated by both oncogenes and tumor suppressors. Indeed, the concomitant introduction of a BRAF\textsuperscript{V600E} mutation and deletion of TP53 and PTEN in astrocytes increased by seven-fold the expression of ACSS2, which contributes to the cytosolic pool of acetyl-CoA, but had little effect on ACSS1, which generates mitochondrial acetyl-CoA [71]. This same paper showed that knockdown of ACSS2 decreased the GBM neurosphere growth and viability, and the authors postulated that this phenotype is due to decreased oxidation of acetyl-CoA in the mitochondria (as discussed above). However, it is possible that ACSS2 promotes GBM growth by funneling extracellular acetate towards lipogenesis in addition to oxidation in the TCA cycle.

De novo lipogenesis continues when cytosolic acetyl-CoA is carboxylated by the enzyme acetyl-CoA carboxylase (ACC) in an ATP-dependent fashion to generate malonyl-CoA. The ACC reaction is the rate limiting step in de novo lipogenesis and it is followed by the reactions of fatty acid synthase (FASN), which catalyzes the multi-step synthesis of the fatty acid palmitate from seven molecules of malonyl-CoA, a single molecule of acetyl-CoA, seven molecules of ATP and 14 molecules of NADPH. The activity of de novo lipogenesis is important for GBM growth. In cell culture models of GBM, forced expression of the vIII variant of EGFR stimulates de novo lipogenesis and growth, which is reversed when ACC is inhibited with small interfering RNAs (siRNAs) [98]. Pharmacologic inhibition of de novo lipogenesis using the adenosine monophosphate-dependent protein kinase (AMPK) agonist 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) causes a similar anti-proliferative effect in EGFR-driven GBM models both in vitro and in vivo [99]. Pharmacologic and genetic inhibition of FASN similarly inhibits the proliferation of GSC cell lines [100] and immortalized GBM cell lines [101]. Clinical grade inhibitors of FASN have been developed and are being investigated in numerous cancers including GBM (NCT03032484).

The dependence of GBM on de novo lipogenesis is governed by increased oncogenic activity, which in turn stimulates sterol regulatory element-binding protein-1 (SREBP-1), a transcription factor, and master regulator of lipogenesis [102,103]. EGFR promotes N-glycosylation of SREBP cleavage-activating protein (SCAP) to active SREBP and drive GBM growth [104,105]. Inhibition of sterol O-acyltransferase (SOAT1) blocks cholesterol esterification and also suppresses GBM growth through blocking SREBP-1-regulated fatty acid synthesis [106]. SREBP is activated by other GBM drivers including PI3K/mTORC1 [107]. Due to the genomic heterogeneity characteristic of GBM, it is possible that the inhibition of SREBP or de novo lipogenesis itself may be a fruitful and unexplored therapeutic strategy in GBM.

In some contexts, the oxidation of fatty acids, rather than their synthesis, seems to govern GBM growth and survival. There is increasing evidence that a population of slowly cycling stem-like cells drives GBM growth and recurrence after therapy [108]. Such “slowly cycling” GBM progenitor cells may depend more heavily on fatty acid oxidation than synthesis [109]. Indeed, fatty acid binding protein 7 (FABP7), a lipid chaperone that mediates fatty acid uptake and subsequent oxidation, is highly expressed in GBM neurospheres and slowly growing progenitor cells, and its inhibition slows the growth and invasiveness of GBM models in vitro and in vivo [109,110]. In support of this hypothesis, primary cultured human GBM cells utilize fatty acids as a primary component of their oxidative metabolism and inhibition of fatty acid oxidation with the compound etomoxir slowed the proliferation of primary GBM cultures in vitro and their tumorigenesis in intracranial mouse models [111]. These findings suggest that lipid metabolism, like most other phenotypes in GBM, is heterogeneous and that combination therapies may be needed to improve patient outcomes.
One potential strategy would be to inhibit both fatty acid synthesis (to affect the rapidly dividing GBM progenitor cells) while simultaneously inhibiting fatty acid oxidation (to affect slowly cycling stem-like cells). However, the therapeutic window for such combined inhibition of oxidation and synthesis is unlikely to be favorable. Since slow cycling cells that depend on fatty acid oxidation may drive recurrences after chemotherapy and/or radiation, a more promising strategy may be to combine etomoxir with initial chemoradiation in patients with GBM.

Like fatty acids, cholesterol can be synthesized de novo or taken up from the environment. Both pathways are important for GBM growth and survival. EGFR-mediated SREBP1 activation in GBM promotes the expression of the low density lipoprotein receptor (LDLR), which is a key mediator of cholesterol uptake [102]. Agents that force the degradation of LDLR and block cholesterol uptake slow the growth of GBM cells in vitro and tumors in vivo. Systemic inhibition of LDLR may have a limited therapeutic window as genetic deletion of this target causes severe hypercholesterolemia and pharmacologic modulation appears to cause neuropsychiatric side effects [112,113]. The de novo synthesis of cholesterol is governed by the activity of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), which is inhibited by the statin drug class. There is conflicting epidemiologic evidence regarding whether the use of statins is associated with improved survival in patients with GBM [114]. Drugs in the statin class have anti-proliferative effects when used alone or in combination with DNA damaging agents in patient-derived GBM cell lines, but the mechanism accounting for this efficacy is uncertain [115]. Similar combination therapies are now being tested in the clinic in a small phase 2 trial, but final results have not yet been published [113].

3.5. Nucleotide Metabolism

Nucleotides are important signaling and structural molecules and are the principal carriers of accessible chemical energy in the cell. Nucleotides consist of a nitrogenous base attached to a sugar molecule (ribose or deoxyribose), which is coupled to phosphate groups. Structurally, nucleotides and deoxynucleotides are principal components of DNA, RNA, and ribosomes. Production of nucleotides is carried out by two main pathways, termed de novo nucleotide synthesis and nucleotide salvage.

De novo synthesis of purines or pyrimidines utilizes one carbon unit, amino acids, ribose, and significant amounts of free energy to generate new nitrogenous base rings from scratch. By contrast, nucleotide salvage involves the conversion of pre-formed bases into nucleotides and requires less energy than de novo synthesis. Conventionally, proliferating cells have a higher reliance on de novo nucleotide synthesis than nucleotide salvage pathways and this appears to be the case in GBM as well. De novo purine synthesis is highly elevated in GBM stem cells and promotes cell growth and tumor formation, which is mediated and maintained by the activity of c-MYC [116]. In some neurosphere models of GBM, de novo pyrimidine synthesis also plays an important role [117]. Salvage pathways are also active in GBM. Nuclear medicine scans using the radiolabeled tracer \textsuperscript{18}F-fluorothymidine routinely show an increased signal in GBM tissue compared to nearby normal brain, but it is not entirely clear whether this finding is due to increased pyrimidine salvage in GBM or simply disruption of the blood brain barrier [118]. Purine salvage pathways are also intact in GBM. Indeed, the ability to scavenge hypoxanthine, the most abundant purine in the CSF, may account for the resistance of GBM to anti-folate therapy [119]. Inhibitors of de novo purine synthesis that act downstream of the hypoxanthine salvage step (which generates inosine monophosphate) may be more effective. There have been preliminary clinical investigations of inhibitors of nucleotide metabolism in GBM. Gemcitabine, a cytidine analog that can be incorporated into DNA or slow deoxynucleotide production by inhibiting ribonucleotide reductase, can cross the blood brain barrier and accumulate into tumors such as GBM at active concentrations [120,121]. Consistent with these observations, a clinical trial combining gemcitabine and radiation for patients with high-grade glioma including GBM showed reasonable safety and promising clinical outcomes [122]. Since nucleotide metabolism is a tractable and established therapeutic target, we are optimistic that the increased understanding of altered nucleotide metabolism in GBM will result in therapeutic advances.
3.6. Alternative Metabolic Pathways and Plasticity

In addition to dysregulation of these canonical metabolic pathways, many other metabolic liabilities in GBM are emerging. The importance of one-carbon reactions across multiple cancers also holds true in GBM. Overexpression of mitochondrial serine hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC) in GBM promotes tumor growth by inhibition of PKM2 activity and reduction of oxygen consumption [123]. 5-methylthioadenosine phosphorylase (MTAP), a key enzyme in the methionine salvage pathway, is deleted in almost half of GBM tumors [124]. MTAP deletion increases dependence on protein arginine methyltransferase 5 (PRMT5) and inhibition of PRMT5 selectively kills MTAP-null cancer cells [125–127], indicating that inhibition of PRMT5 is a potential therapy for MTAP-deleted tumors. Further in vitro and in vivo studies have demonstrated the antitumor effects of PRMT5 inhibitors in GBM and underscored the importance of developing it in the clinic [128]. Clinical trials are underway (NCT02783300) to evaluate the escalated dosage of a PRMT5 inhibitor in a variety of solid tumors including GBM. The clinical development of inhibitors of one-carbon metabolism has been more fraught and clinical trials are not currently ongoing [129]. A more tractable strategy may be to alter one-carbon metabolism by altering diet. Indeed, humans and mice on a methionine-restricted diet had depleted circulating antioxidant and nucleotide levels and this dietary modification increased the responsiveness of tumors in mice to both radiation and chemotherapy [130].

4. IDH1/2 Mutation and 2-Hydroxyglutarate

In 2008, exome-sequencing studies identified a novel mutation of IDH1 in 12% of GBM patients [131]. Further studies have found that IDH1, or IDH2 mutation, happens in ~80% of WHO grade II–III gliomas and secondary GBM [40]. Mutations in IDH1 mainly affect R132, which is the binding site for isocitrate, and R132H is the most common alteration, comprising >80% of all IDH1 mutations in gliomas [40,131–133]. Mutations in IDH2 exclusively affect R172 and R140, with the former being structurally analogous to IDH1 R132 [40,132]. In addition to reducing affinity for isocitrate and losing its normal catalytic activity [134], mutant IDH1 or IDH2 also gained the function of catalyzing the reduction of α-KG to produce the (R) enantiomer of 2-hydroxyglutarate, (R)-2HG (also known as D-2HG), which accumulates in IDH1 or IDH2 mutated gliomas to millimolar concentrations [135] (Figure 2). Most IDH1 mutant tumors still retain one wild-type IDH1 allele and disruption of the residual wild-type IDH1 allele decreases D-2HG production, indicating that IDH1 mutant-induced D-2HG production is probably dependent on wild-type IDH1 [136]. Initial studies suggested that this dependence might be due to the substrate channeling or cooperative effects exiting in the IDH1 wt/mut heterodimers [137,138], however the recently published crystal structure of the IDH1 wt/mut heterodimer fails to show physical association between the active sites of the wild-type and the mutant, which suggests that substrate channeling does not occur [139].

A complete understanding of how mutant IDH and D-2HG affects GBM cells is still developing. The IDH1 mutation contributes to tumorigenesis through regulation of the HIF-1α pathway, alteration of histone and DNA methylation, activation of glutaminolysis, and increased sensitivity to glucose deprivation [134,140,141] (Figure 2). These tumorigenic properties of mutant IDH are due to its product (D)-2HG, which has accordingly been considered an oncometabolite. Due to its structural similarity to alpha-ketoglutarate (α-KG), D-2HG inhibits DNA and histone demethylases, namely the ten-eleven translocation enzymes (TETs) and lysine demethylases (KDMs) [142,143], to block differentiation of non-transformed cells [146]. How the IDH1 mutation affects HIF-1α activity is still controversial. IDH1 mutant glioma cells reduce the production of α-KG and increase HIF-1α and its target genes (GLUT1, VEGF, and PDK1) to stimulate tumor growth and angiogenesis [134], whereas IDH1 mutants have also been shown to stimulate EglN prolyl 4-hydroxylase, which destabilizes HIF-1α and diminishes the expression of its target genes to promote transformation [144]. Mutant IDH1 cooperated with PDGFA and inactivation of CDKN2A, ATRX, and PTEN to promote glioma development [145]. Moreover, pyruvate dehydrogenase (PDH) activity is downregulated in a 2HG-dependent manner in
IDH mutant GBM cells, leading to reduced pyruvate flux into the TCA cycle and decreased glutamate levels, and finally promoted colony formation and cell proliferation [141].

Targeting mutant IDH1 to normalize (D)-2HG levels is an attractive cancer therapeutic strategy in gliomas. Inhibitor of mutant IDH1 (AGI-5198) impaired the growth of IDH1-mutant but not IDH1-wild-type glioma cells by increasing the expression of genes associated with gliogenic differentiation [146]. Phase I studies of another two mutant IDH1 inhibitors (AGI-881, NCT02481154; AG-120) showed a favorable safety profile and potential efficacy in patients with IDH mutated gliomas [147]. Promisingly, ivosidenib (AG-120) has been approved by FDA as first-line treatment for acute myeloid leukemia (AML) with IDH1 mutation after a positive clinical trial (NCT02074839), further indicating the therapeutic potential of targeting this alteration.

While much data suggests that inhibition of D-2HG production may benefit patients with IDHmutGBM, there are several lines of evidence that suggests an alternative approach of targeting not D-2HG itself, but rather the vulnerabilities that bestows on IDH mutant tumors. Patients with IDHmutGBM have a better prognosis than those with IDHwtGBM [131], but it is not clear if this is due to D-2HG-mediated vulnerabilities or different natural histories between these two tumor types. A recent study showed that inhibition of Bcl-xL, only in the presence of D-2HG, could significantly induce more apoptosis in IDH1-mutant cells than wild-type IDH1 cells [148]. The reason is that D-2HG-mediated energy depletion activates AMPK and then blunts protein synthesis and mTOR signaling, leading to a decline of Mcl-1, which sensitizes glioblastoma cells to Bcl-xL-inhibition-mediated apoptosis. Furthermore, mutant IDH1 decreases the HIF-1α-responsive gene, LDHA, which is essential for glycolysis and is overexpressed in cancers, through IDH-mutant-induced methylation of LDHA promoter [149], finally limiting the rapid cell growth of high-grade glioma. D-2HG also inhibits ATP synthase and mTOR signaling downstream to decrease tumor cell growth and viability [150]. D-2HG also inhibits the branched-chain amino acid transaminase 1 (BCAT1) and 2 (BCAT2), which renders IDH1 mutant glioma cells dependent on glutaminase and increases their sensitivity to oxidative stress [151].

There is controversy as to whether the IDH mutation promotes or impairs the ability of gliomas to repair DNA damage. D-2HG has been reported to inhibit homologous recombination by inhibiting the activity of histone lysine demethylases, thereby increasing the sensitivity of these cancers to inhibitors and alkylating agents such as temozolomide [145,152,153]. Consistent with these findings, inhibition of 2HG production makes IDH mutant cell line models of glioma resistant to radiation [154]. However, a genetically engineered IDH mutant astrocytoma, in which p53 and ATRX were also inactivated, showed an enhanced ability to repair DNA due to upregulation of homologous recombination [155]. In this model, the IDH mutation increased the expression of key components of the DNA damage response by increasing histone methylation. These epigenetic changes resulted in profoundly radioresistant tumors, and this resistance could be overcome with inhibitors of ATM or CHK1/2. These apparently discordant results have important complications about the best strategies to design combination treatments for patients with IDHmutGBM and a final answer will likely have to wait for the clinical trials themselves.

Thus, the effects of the IDH1 mutation and D-2HG in GBMs may be context-dependent, which has important implications for therapy decisions. Early in tumorigenesis, it may be beneficial to inhibit the production of D-2HG to limit the initial transforming events. However, once a tumor is established, it may become less dependent on D-2HG for growth and that inhibition of mutant IDH may be less effective [156]. In this situation, a more promising strategy may be to inhibit the D-2HG-induced therapeutic vulnerabilities. This approach is supported by preclinical evidence. In one study, D-2HG depletion failed to inhibit the growth of established IDH1 mutant glioma cell lines and tumors, but rendered these tumors exquisitely sensitive to NAMPT inhibition [157]. This phenotype occurred because D-2HG inhibits the NAD⁺ producing enzyme Naprt1, which causes IDH mutant cells to preferentially rely on NAMPT for NAD⁺ generation. Thus, while inhibitors of mutant IDH1 may prevent tumor formation or growth early in the disease course, their ability to reduce D-2HG may reverse some of the therapeutically attractive vulnerabilities of IDH mutant tumors.
5. Metabolic Targeting to Sensitize GBM to Standard Therapies

5.1. Radiation

Radiotherapy is one of only a handful of treatments that improves survival in patients with GBM, and the modulation of radiation resistance is of significant interest to further improving outcomes. Aberrant metabolic pathways intersect with many mediators of radiation resistance and targeting these abnormalities may be helpful to improve GBM radio-sensitivity (Figure 3).

High rates of glycolysis correlate with radiation resistance in multiple cancer models and inhibition of glycolysis can help overcome this resistance. Knockdown of the glycolytic enzyme HK2, reduced GBM growth in vitro and in vivo by increasing radiation-induced apoptosis [61,158]. Pharmacologic inhibition of upper glycolysis with 2-DG shows radio-sensitizing effects in multiple solid tumors, including GBM [65]. Inhibiting lower glycolysis has similar effects. Dichloroacetate (DCA) activates pyruvate dehydrogenase by inhibiting its regulatory kinase (pyruvate dehydrogenase kinase). Thus DCA promotes the oxidation of glucose and limits its conversion to lactate [159,160].

DCA can augment the DNA double-strand breaks induced by radiotherapy and effectively sensitize GBM to radiotherapy in both in vitro and in vivo models by reversing radiotherapy-induced glycolytic metabolism under hypoxia conditions [161]. DCA crosses the blood–brain barrier and is well tolerated in patients, but its efficacy in GBM is uncertain [162]. Whether DCA retains its radiosensitizing properties in patients with GBM is unknown.

NADPH is a critical reductant that facilitates survival in the face of numerous pro-oxidants, including radiation. IDH1 is the most upregulated NADPH-producing enzyme in IDHwtGBM [83] and knockdown of wild-type IDH1 reduced NADPH levels and radiosensitized GBM in vitro and in vivo by inducing accelerated cellular senescence [82]. These data suggest that inhibiting wild type IDH in IDHwtGBM might be a reasonable therapeutic strategy.

Whether mutant IDH should be inhibited in combination with radiation is less straightforward. As discussed above, the IDH1 mutation causes the accumulation of 2HG, which decreases the ability of gliomas to repair DNA [155]. These data suggest that mutant IDH tumors may be more sensitive to radiation and that inhibition of 2HG may be radioprotective. Indeed, although inhibition of IDH1 mutant with a selective IDH1mt inhibitor (AGI-5198) impaired glioma tumor growth in vitro and in vivo by blocking the production of 2HG [146], this IDH1mt inhibitor was reported to radio-protect IDH1 mutant cancer cells by decreasing radiation-induced ROS levels, DNA double-strand breaks and cell death, indicating that IDH1mt inhibition limits radiation efficacy [154]. If, on the other hand, 2HG actually promotes DNA repair by promoting ATM expression and HR activity, it may make sense to combine radiation and inhibition of mutant IDH [155]. Further study is needed to determine whether or how best to combine radiotherapy with inhibition of mutant IDH.
NAD$^+$ is a critical metabolic co-factor that also plays a role in the DNA damage response. Poly(ADP-ribose) polymerases (PARPs), key enzymes in the base excision repair (BER) and single-strand break repair (SSBR) pathways [163], are major consumers of NAD$^+$ [164]. The catalytic activity of PARP-1 converts NAD$^+$ into long and branched chains of PAR, which rapidly recruit DNA repair factors to compromised sites of DNA damage [165]. PARP inhibitors, which compete with NAD$^+$ at the catalytic site of PARPs, or trap PARPs to DNA, increase the radio-sensitivity of GBM in both in vitro and in vivo studies [166–168]. Other strategies to limit NAD$^+$ availability have similar effects on radiosensitivity. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD$^+$ salvage pathway that converts nicotinamide to NAD$^+$. NAMPT is up-regulated in GBM stem-like cells following radiation and knock down or pharmacological inhibition of NAMPT reversed radio-resistance [169]. Clinical trials of NAMPT inhibitors have been performed as monotherapy, but were discontinued due to toxicity and minimal activity [170]. Whether these agents would have had efficacy in combination with radiation is unknown.

When oxygen is present, conventional radiotherapy mediates the majority of its DNA damage through reactive oxygen species (ROS) such as O$_2^-$, H$_2$O$_2$, and –OH. Thus, potentiating ROS levels or depleting antioxidants are rationale metabolic strategies to augment the radiation response. High dose ascorbate acid (AA) dramatically increases ROS within cancer cells, either due to its ability to inhibit glycolysis or through interactions with labile iron [171–173]. Furthermore, high dose ascorbate induces double stranded breaks (DSBs) and radio-sensitizes GBM cells through a ROS-mediated mechanism [174]. This combination strategy is now being explored clinically in a variety of cancers including glioma with promising early results (NCT02344355) [175,176].

Glutamine metabolism is also involved in modulating ROS and oxidative stress, because its metabolism by GLS generates glutamate, one of the three amino acids used to synthesize the key antioxidant glutathione [177,178]. IDHmtGBMs are exquisitely dependent on GLS to generate glutamate, because their high levels of (R)2HG inhibit the alternative BCAT pathway of glutamate generation. Thus, treatment with GLS inhibitors depletes both glutamate and glutathione in IDH mutant glioma models. Consistent with these findings, the glutaminase inhibitor CB-839 specifically sensitized IDH mutant glioma cells to oxidative stress in vitro and to radiation in vitro and in vivo [151]. CB-839 is now being evaluated in combination with radiation therapy and temozolomide in open-label Phase Iib clinical trials for patients with IDH-mutated diffuse or anaplastic astrocytoma (NCT03528642).

Inhibitors of nucleotide metabolism have been effectively combined with radiation across numerous malignancies for decades. This strategy has been explored in GBM as well. Gemcitabine, which inhibits deoxynucleotide formation by inhibiting ribonucleotide reductase, has been combined with radiation in the clinic, where it was well tolerated and yielded favorable outcomes in the pre-temozolomide era [179]. Whether inhibitors of nucleotide metabolism would have a favorable safety and efficacy profile when combined with temozolomide is not certain.

5.2. Chemotherapy

Alkylating chemotherapy is a standard of care in the treatment of GBM. Many patients with GBM exhibit intrinsic resistance to chemotherapy and those that do initially respond eventually develop recurrences as well [180,181]. Abnormal metabolic pathway utilization may contribute to this resistance phenotype and its inhibition may help overcome resistance to alkylating chemotherapy in GBM. Inhibition of glycolysis at the hexokinase step either with 3-bromopyruvate, 2-deoxyglucose or genetic knockdown of hexokinase confers modest sensitization to temozolomide in GBM cell lines and intracranial tumor models [61,182,183]. Dichloroacetate, which inhibits glycolysis more distally and promotes the oxidation of glucose-derived carbons in the mitochondria, combines less favorably to temozolomide [184]. The mechanisms governing these favorable and unfavorable combinations have not been studied and it remains unclear what glucose-derived metabolites or co-factors are responsible for mediating temozolomide resistance.
Non-glycolytic metabolic enzymes may also mediate temozolomide resistance. Long noncoding RNAs TP73-AS1 enhances the resistance of GBM cancer stem cells to TMZ by promoting the expression of ALDH1A1, which encodes the aldehyde dehydrogenase 1 family member A1 protein and is enriched in cancer stem cell populations. ALDH1 inhibitors, which mark cells with stem-like properties, increased the sensitivity of GBM cells to TMZ [185]. ALDH inhibitors are now being investigated in clinical trials in combination with temozolomide and radiation and preliminary results suggest that the combination is well tolerated and may have efficacy in subsets of GBM patients [186].

The nitrosourea class of chemotherapies is the main cytotoxic alternative to TMZ for patients with GBM [187]. 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP), a more stable derivative of HK2 inhibitor 3-BrPA, depletes ATP by inhibiting glycolysis [188]. Glioblastoma stem cells (GSCs) that are resistant to single agent TMZ or the nitrosurea carmustine are sensitized to both by 3-BrOP, which depletes ATP and inhibits carmustine-induced DNA repair [189]. In addition to this intrinsic resistance, GSCs become resistant to nitrosoureas when they are in hypoxic conditions. This hypoxia-induced nitrosurea resistance is also overcome when cells are treated by 3-BrPA analogs [190].

5.3. Targeted Therapy

Molecularly targeted therapies have shown little activity to date in GBM. Most GBMs exhibit activation of the PI3K/AKT/mTOR pathway, which provided a strong rationale for the use of mTOR inhibitors in this disease [11]. While some trials are still ongoing, initial reports of single agent mTOR inhibitors were disappointing [191,192]. Combining inhibition of mTOR with standard chemoradiation yielded similarly disappointing results [193]. Metabolic adaptation may underlie resistance to mTOR inhibition in GBM. Indeed, treatment with mTOR inhibitors increases GLS expression and glutamate levels and inhibition of GLS sensitizes GBM cell lines and xenografts to mTOR inhibitors [85]. Similar synergism between GLS and mTOR inhibitors is seen in other cancers as well [194], which suggests this combination may be worthy of clinical investigation in GBM as well as other diseases.

Anti-angiogenic therapy has had minimal success in improving outcomes for patients with GBM [195,196]. Metabolic adaptation may also cause resistance to this family of targeted therapies. Treatment with bevacizumab increases the uptake of glucose and its conversion into lactate in orthotopic patient-derived xenograft models of GBM [197]. Similarly, bevacizumab treatment reduces the flow of glucose-derived carbons into the TCA cycle. Whether this metabolic adaption is a direct effect of bevacizumab or simply a result of bevacizumab-induced hypoxia is unknown [198]. Regardless, these observations suggest that the efficacy of bevacizumab could be augmented by a PDH activator such as DCA, but to our knowledge this combination has not been tested.

5.4. Immunotherapy

Immune-based therapies have become standard treatment options for many cancers [199,200]. These therapies are also under investigation in GBM, but results thus far have been disappointing. Inhibitors of immune checkpoint receptors have been used and are well tolerated in GBM but results to date have been mixed. Indeed, the CheckMate-143 clinical trial randomized 369 patients with recurrent GBM to either bevacizumab or nivolumab (an inhibitor of the programmed cell death 1 checkpoint) treatment. The one-year overall survival was approximately 40% in both arms and there were no changes in the median overall survival [201]. Similar results were seen in primary GBM in the CheckMate-498 trial, which randomized over 500 patients with MGMT-umethylated primary GBMs to treatment with either radiation with temozolomide or radiation with nivolumab. There was no significant improvement in survival in the nivolumab treatment arm [202]. Whether nivolumab will have efficacy in MGMT-methylated GBM will be determined in the pending CheckMate-548 trial. Despite, these disappointing results, a recent study showed that blockade of PD-1 signaling prior to surgical resection in recurrent GBM may be more efficacious than PD-1 administration after resection [203]. Thus, it is possible that the neoadjuvant immune checkpoint blockade could prove efficacious in both de novo and recurrent GBM. Other immune-based therapies including additional
checkpoint inhibitors, chimeric antigen receptor (CAR) T cells, and viral-based therapies remain under investigation in GBM [204].

The metabolic environment of GBM may be immunosuppressive and limit the efficacy of immune-based therapies. Tumor-derived lactate suppresses T cell function by blocking lactate export and suppressing their ability to maintain aerobic glycolysis [205]. Lactate similarly inhibits type 1 interferon signaling [206]. Hence, the high lactate concentrations found within many GBMs may contribute to the disappointing clinical trial results of immunotherapies in this disease. Targeting lactate metabolism by either inhibiting GBM glycolysis of lactate export via the monocarboxylate transporter could thus be unexplored strategies to improve immunotherapy efficacy in this disease [207,208].

Most GBMs also express the metabolic enzyme indoleamine 2,3 dioxygenase 1 (IDO1), which catalyzes the conversion of tryptophan to kynurenine [209]. The metabolic consequences of IDO1 activity (e.g., low tryptophan and high kynurenine) suppress the activity of T cells through a variety of mechanisms and may also limit the efficacy of immunotherapy in GBM. In support of this hypothesis, pharmacologic inhibition of IDO augments the efficacy of immune checkpoint blockade in intracranial mouse models of GBM [210]. Unfortunately, initial clinical trial results combining IDO inhibitors with a checkpoint blockade in pancreatic cancer and melanoma were disappointing and enthusiasm for continued testing of this combination in clinical trials is waning [211].

6. Conclusions and Future

The number of treatments that have impacted survival in GBM can be counted on a single hand. The past decade has seen tremendous elucidation of the genetic abnormalities and liabilities that characterize GBM, but these have not yet translated into useful clinical strategies. Targeting altered metabolism rather than genetic abnormalities is a promising alternative strategy that we hope may provide some benefit in this challenging disease. Inhibiting mutated IDH or exploiting the liabilities conferred by its metabolic product (R)-2HG represent promising metabolic strategies to improve outcomes in IDHmtGBM. Since the IDH mutation is an early oncogenic event, its presence (and the presence of (R)-2HG is relatively homogeneous in these tumors, which are otherwise largely characterized by heterogeneity. The path forward for metabolic therapy in IDHwtGBM is less clear. TMZ and radiation, two of the successful therapies in IDHwtGBM place intense metabolic demands on cells and we are hopeful that combining metabolic inhibitors with these treatments is perhaps the most reasonable first strategy to pursue.

Funding: This work was supported by a University of Michigan Cancer Center Core grant (P30CA046592) as well as grants from the American Cancer Society, the Forbes Institute for Cancer Discovery, and the Jones Family Foundation Fund within the Chad Carr Pediatric Brain Tumor Center (D.R.W). W.Z is supported by the Postdoctoral Translational Scholar Program (F053054) from the Michigan Institute for Clinical & Health Research, Postdoctoral Translational Scholar Program.

Acknowledgments: We thank Sriram Venneti and Drew Pratt for their helpful comments regarding the pathologic classifications of gliomas.

Conflicts of Interest: D.R.W declares research funding from Agios pharmaceuticals. W.Z. has no conflicts to declare.

References

1. Cloughesy, T.F.; Cavenee, W.K.; Mischel, P.S. Glioblastoma: From molecular pathology to targeted treatment. Annu. Rev. Pathol. 2014, 9, 1–25. [CrossRef] [PubMed]
2. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [CrossRef] [PubMed]
3. Brown, T.J.; Brennan, M.C.; Li, M.; Church, E.W.; Brandmeir, N.J.; Rakszawski, K.L.; Patel, A.S.; Rizk, E.B.; Suki, D.; Sawaya, R.; et al. Association of the Extent of Resection with Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2016, 2, 1460–1469. [CrossRef] [PubMed]
4. Stupp, R.; Taillibert, S.; Kanner, A.A.; Kesari, S.; Steinberg, D.M.; Toms, S.A.; Taylor, L.P.; Lieberman, F.; Silvani, A.; Fink, K.L.; et al. Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. *JAMA* 2015, 314, 2535–2543. [CrossRef] [PubMed]

5. Weller, M.; van den Bent, M.; Hopkins, K.; Tonn, J.C.; Stupp, R.; Falini, A.; Cohen-Jonathan-Moyal, E.; Frappaz, D.; Henriksson, R.; Balana, C.; et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. *Lancet. Oncol.* 2014, 15, e395–e403. [CrossRef]

6. Sullivan, J.P.; Nahed, B.V.; Madden, M.W.; Oliveira, S.M.; Springer, S.; Bhere, D.; Chi, A.S.; Wakimoto, H.; Rothenberg, S.M.; Sequist, L.V.; et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. *Cancer Discov.* 2014, 4, 1299–1309. [CrossRef] [PubMed]

7. Omuro, A.; DeAngelis, L.M. Glioblastoma and other malignant gliomas: A clinical review. *JAMA* 2013, 310, 1842–1850. [CrossRef] [PubMed]

8. van Linde, M.E.; Brahm, C.G.; de Witt Hamer, P.C.; Reijneveld, J.C.; Bruynzeel, A.M.E.; Vandertop, W.P.; van de Ven, P.M.; Wagemakers, M.; van der Weide, H.L.; Enting, R.H.; et al. Treatment outcome of patients with recurrent glioblastoma multiforme: A retrospective multicenter analysis. *J. Neuro Oncol.* 2017, 133, 183–192. [CrossRef] [PubMed]

9. Felsberg, J.; Hentschel, B.; Kaulich, K.; Gramatzki, D.; Zacher, A.; Malzkorn, B.; Sabel, M.; Simon, M.; Westphal, M.; et al. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. *Clin. Cancer Res.* 2017, 23, 6846–6855. [CrossRef] [PubMed]

10. Francis, J.M.; Zhang, C.Z.; Maire, C.L.; Jung, J.; Manzo, V.E.; Adalsteinsson, V.A.; Homer, H.; Haidar, S.; Blumenstiel, B.; Pedamallu, C.S.; et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. *Cancer Discov.* 2014, 4, 956–971. [CrossRef] [PubMed]

11. Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. *Cell* 2013, 155, 462–477. [CrossRef] [PubMed]

12. Di Stefano, A.L.; Fucci, A.; Frattini, V.; Labussiere, M.; Mokhtari, K.; Zoppoli, P.; Marie, Y.; Bruno, A.; Boisselier, B.; Giry, M.; et al. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. *Clin. Cancer Res.* 2015, 21, 3307–3317. [CrossRef] [PubMed]

13. Singh, D.; Chan, J.M.; Zoppoli, P.; Niola, F.; Sullivan, R.; Castano, A.; Liu, E.M.; Reichel, J.; Porrtai, P.; Pellegratta, S.; et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. *Science* 2012, 337, 1231–1235. [CrossRef] [PubMed]

14. Xu, X.; Bao, Z.; Liu, Y.; Jiang, K.; Zhi, T.; Wang, D.; Fan, L.; Liu, N.; Ji, J. PBX3 positive feedback loop enhances mesenchymal phenotype to promote glioblastoma migration and invasion. *J. Exp. Clin. Cancer Res.* 2018, 37, 158. [CrossRef] [PubMed]

15. Galanis, E.; Anderson, S.K.; Latky, J.M.; Ulm, J.H.; Giannini, C.; Kumar, S.K.; Kimlinger, T.K.; Northfelt, D.W.; Flynn, P.J.; Jaeckle, K.A.; et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): A north central cancer treatment group trial. *Clin. Cancer Res.* 2013, 19, 4816–4823. [CrossRef] [PubMed]

16. Wen, P.Y.; Touat, M.; Alexander, B.M.; Mellinghoff, I.K.; Ramkissoon, S.; McCluskey, C.S.; Pelton, K.; Haidar, S.; Basu, S.S.; Gaffey, S.C.; et al. Buparlisib in Patients with Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. *J. Clin. Oncol.* 2019, 37, 741–750. [CrossRef] [PubMed]

17. Pitz, M.W.; Eisenhauer, E.A.; MacNeil, M.V.; Thiessen, B.; Easaw, J.C.; Macdonald, D.R.; Eisenstat, D.D.; Kakumanu, A.S.; Salim, M.; Chalchal, H.; et al. Phase II study of PX-866 in recurrent glioblastoma. *Neuro Oncol.* 2015, 17, 1270–1274. [CrossRef] [PubMed]

18. Gobin, M.; Nazarov, P.V.; Warta, R.; Timmer, M.; Reifenberger, G.; Felsberg, J.; Vallar, L.; Chalmers, A.J.; Herold-Mende, C.C.; Goldbrunner, R.; et al. A DNA repair and cell cycle gene expression signature in primary and recurrent glioblastoma: Prognostic value and clinical implications. *Cancer Res.* 2019. [CrossRef] [PubMed]

19. Willems, E.; Dedobbeleer, M.; Digregorio, M.; Lombard, A.; Goiffert, N.; Lumapat, P.N.; Lambert, J.; Van den Ackerveken, P.; Szpakowska, M.; Chevigne, A.; et al. Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration. *Oncogene* 2019, 38, 73–87. [CrossRef] [PubMed]
20. Michaud, K.; Solomon, D.A.; Oermann, E.; Kim, J.S.; Zhong, W.Z.; Prados, M.D.; Ozawa, T.; James, C.D.; Waldman, T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010, 70, 3228–3238. [CrossRef]

21. Cen, L.; Carlson, B.L.; Schroeder, M.A.; Ostrem, J.L.; Kitange, G.J.; Mladen, A.C.; Fink, S.R.; Decker, P.A.; Wu, W.; Kim, J.S.; et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012, 14, 870–881. [CrossRef] [PubMed]

22. Talukdar, S.; Pradhan, A.K.; Bhoopathi, P.; Shen, X.N.; August, L.A.; Windle, J.J.; Sarkar, D.; Furnari, F.B.; Cavenee, W.K.; Das, S.K.; et al. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proc. Natl. Acad. Sci. USA 2018, 115, 5768–5773. [CrossRef] [PubMed]

23. Costa, B.; Bendinelli, S.; Gabelloni, P.; Da Pozzo, E.; Daniele, S.; Scatena, F.; Vanacore, R.; Campiglia, P.; Bertamino, A.; Gomez-Monterrey, I.; et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS ONE 2013, 8, e72281. [CrossRef] [PubMed]

24. Verreault, M.; Schmitt, C.; Goldwirt, L.; Pelton, K.; Haidar, S.; Levasseur, C.; Guehennec, J.; Knoff, D.; Labussiere, M.; Marie, Y.; et al. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin. Cancer Res. 2016, 22, 1185–1196. [CrossRef] [PubMed]

25. Jain, H.V.; Nor, J.E.; Jackson, T.L. Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral angiogenesis. Bull. Math. Biol. 2008, 70, 89–117. [CrossRef] [PubMed]

26. Batchelor, T.T.; Reardon, D.A.; de Groot, J.F.; Wick, W.; Weller, M. Antiangiogenic therapy for glioblastoma: Current status and future prospects. Clin. Cancer Res. 2014, 20, 5612–5619. [CrossRef] [PubMed]

27. Preusser, M.; Lim, M.; Hafler, D.A.; Reardon, D.A.; Sampson, J.H. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 2015, 11, 504–514. [CrossRef] [PubMed]

28. Nduom, E.K.; Wei, J.; Yaghi, N.K.; Huang, N.; Kong, L.Y.; Gabrusiewicz, K.; Ling, X.; Zhou, S.; Ivan, C.; Chen, J.Q.; et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016, 18, 195–205. [CrossRef] [PubMed]

29. Berghoff, A.S.; Kiesel, B.; Widhalm, G.; Rajky, O.; Ricken, G.; Wohrer, A.; Dieckmann, K.; Filipits, M.; Brandstetter, A.; Weller, M.; et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015, 17, 1064–1075. [CrossRef] [PubMed]

30. Qazi, M.A.; Vora, P.; Venugopal, C.; Sidhu, S.S.; Moffat, J.; Swanton, C.; Singh, S.K. Intratumoral heterogeneity: Pathways to treatment resistance and relapse in human glioblastoma. Ann. Oncol. 2017, 28, 1448–1456. [CrossRef]

31. Harbaniang, C.; Kma, L. Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells. Asian Pac. J. Cancer Prev. 2018, 19, 2377–2390. [CrossRef] [PubMed]

32. Tennant, D.A.; Duran, R.V.; Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10, 267–277. [CrossRef] [PubMed]

33. Wesseling, P.; Capper, D. WHO 2016 Classification of gliomas. Neuropathol. Appl. Neurobiol. 2018, 44, 139–150. [CrossRef] [PubMed]

34. Perry, A.; Wesseling, P. Histologic classification of gliomas. Handb. Clin. Neurol. 2016, 134, 71–95. [CrossRef] [PubMed]

35. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [CrossRef] [PubMed]

36. van den Bent, M.J.; Brandes, A.A.; Taphoorn, M.J.B.; Kros, J.M.; Kouwenhoven, M.C.M.; Delattre, J.-Y.; Berens, H.J.J.A.; Frenay, M.; Tijssen, C.C.; Grisold, W.; et al. Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 2012, 31, 344–350. [CrossRef] [PubMed]

37. Buckner, J.C.; Shaw, E.G.; Pugh, S.L.; Chakravarti, A.; Gilbert, M.R.; Barger, G.R.; Coons, S.; Ricci, P.; Bullard, D.; Brown, P.D.; et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N. Engl. J. Med. 2016, 374, 1344–1355. [CrossRef] [PubMed]

38. Reuss, D.E.; Mamajian, Y.; Schirmpf, D.; Capper, D.; Hovestadt, V.; Kratz, A.; Sahm, F.; Koelsche, C.; Korshunov, A.; Olar, A.; et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: A grading problem for WHO. Acta Neuropathol. 2015, 129, 867–873. [CrossRef] [PubMed]

39. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 2015, 372, 2481–2498. [CrossRef] [PubMed]
Cancers 2019, 11, 1231

40. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. *N. Engl. J. Med.* 2009, *360*, 765–773. [CrossRef]

41. Eckel-Passow, J.E.; Lachance, D.H.; Molinaro, A.M.; Walsh, K.M.; Decker, P.A.; Sicotte, H.; Pekmezci, M.; Rice, T.; Kosei, M.L.; Smirnov, I.V.; et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N. Engl. J. Med.* 2015, *372*, 2499–2508. [CrossRef] [PubMed]

42. Khuong-Quang, D.-A.; Buczkowicz, P.; Rakopoulos, P.; Liu, X.-Y.; Fontebasso, A.M.; Bouffet, E.; Bartels, U.; Albrecht, S.; Schwartzentuber, J.; Letourneau, L.; et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathol.* 2012, *124*, 439–447. [CrossRef]

43. Marin-Valencia, I.; Yang, C.; Mashimo, T.; Cho, S.; Baek, H.; Yang, X.L.; Rajagopalan, K.N.; Maddie, M.; Vemireddy, V.; Zhao, Z.; et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. *Cell Metab.* 2012, *15*, 827–837. [CrossRef] [PubMed]

44. Wolf, A.; Agnihotri, S.; Munoz, D.; Guha, A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. *Neurobiol. Dis.* 2011, *44*, 84–91. [CrossRef] [PubMed]

45. Muller, F.L.; Colla, S.; Aquilanti, E.; Manzo, V.E.; Genovese, G.; Lee, J.; Eisenson, D.; Narurkar, R.; Deng, P.; Nezi, L.; et al. Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature* 2012, *488*, 337–342. [CrossRef] [PubMed]

46. Sanzey, M.; Abdul Rahim, S.A.; Oudin, A.; Dirkse, A.; Kaoma, T.; Vallar, L.; Herold-Mende, C.; Bjerkvig, R.; Golebiowska, A.; Niclou, S.P. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma. *PloS ONE* 2015, *10*, e0123544. [CrossRef] [PubMed]

47. Prabhu, A.; Sarcar, B.; Miller, C.R.; Kim, S.H.; Nakano, I.; Forsyth, P.; Chinnaiyan, A. Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. *Neuro Oncol.* 2015, *17*, 1220–1230. [CrossRef] [PubMed]

48. Lee, J.H.; Liu, R.; Li, J.; Zhang, C.; Wang, Y.; Cai, Q.; Qian, X.; Xia, Y.; Zheng, Y.; Piao, Y.; et al. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. *Nat. Commun.* 2017, *8*, 949. [CrossRef] [PubMed]

49. Tateishi, K.; Iafrite, A.J.; Ho, Q.; Curry, W.T.; Batchelor, T.T.; Flaherty, K.T.; Onozato, M.L.; Lelic, N.; Sundaram, S.; Cahill, D.P.; et al. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. *Clin. Cancer Res.* 2016, *22*, 4452–4465. [CrossRef] [PubMed]

50. Hodgson, J.G.; Yeh, R.F.; Ray, A.; Wang, N.J.; Smirnov, I.; Yu, M.; Hariono, S.; Silber, J.; Feiler, H.S.; Gray, J.W.; et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. *Neuro Oncol.* 2009, *11*, 477–487. [CrossRef] [PubMed]

51. Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008, *455*, 1061–1068. [CrossRef] [PubMed]

52. Masui, K.; Tanaka, K.; Akhavan, D.; Babic, I.; Gini, B.; Matsutani, T.; Iwanami, A.; Liu, F.; Villa, G.R.; Gu, Y.; et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. *Cell Metab.* 2013, *18*, 726–739. [CrossRef] [PubMed]

53. David, C.J.; Chen, M.; Assanah, M.; Canoll, P.; Manley, J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. *Nature* 2010, *463*, 364–368. [CrossRef] [PubMed]

54. Mazurek, S.; Boschez, C.B.; Hugo, F.; Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin. Cancer Biol.* 2005, *15*, 300–308. [CrossRef] [PubMed]

55. Christofo, H.R.; Vander Heiden, M.G.; Harris, M.H.; Ramanathan, A.; Gerszten, R.E.; Wei, R.; Fleming, M.D.; Schreiber, S.L.; Cantley, L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature* 2008, *452*, 230–233. [CrossRef]

56. Yang, W.; Xia, Y.; Hawke, D.; Li, X.; Liang, J.; Xing, D.; Aldape, K.; Hunter, T.; Alfred Yung, W.K.; Lu, Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. *Cell* 2012, *150*, 685–696. [CrossRef] [PubMed]

57. Liang, J.; Cao, R.; Zhang, Y.; Xia, Y.; Zheng, Y.; Li, X.; Wang, L.; Yang, W.; Lu, Z. PKM2 dephosphorylation by Cdk25A promotes the Warburg effect and tumorigenesis. *Nat. Commun.* 2016, *7*, 12431. [CrossRef]
58. Liang, J.; Cao, R.; Wang, X.; Zhang, Y.; Wang, P.; Gao, H.; Li, C.; Yang, F.; Zeng, R.; Wei, P.; et al. Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. *Cell Res.* 2017, 27, 329–351. [CrossRef] [PubMed]

59. Hosios, A.M.; Fiske, B.P.; Gui, D.Y.; Vander Heiden, M.G. Lack of Evidence for PKM2 Protein Kinase Activity. *Mol. Cell* 2015, 59, 850–857. [CrossRef]

60. Zhang, Y.; Yu, G.; Chu, H.; Wang, X.; Xiong, L.; Cai, G.; Liu, R.; Gao, H.; Tao, B.; Li, W.; et al. Macrophage-Associated PGK1 Phosphorylation Promotes Aerobic Glycolysis and Tumorigenesis. *Mol. Cell* 2018, 71, 201–215. [CrossRef]

61. Wolf, A.; Agnihotri, S.; Micallef, J.; Mukherjee, J.; Sabha, N.; Cairns, R.; Hawkins, C.; Guha, A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. *J. Exp. Med.* 2011, 208, 313–326. [CrossRef] [PubMed]

62. Wilson, J.E. Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. *J. Exp. Biol.* 2003, 206, 2049–2057. [CrossRef] [PubMed]

63. Patra, K.C.; Wang, Q.; Bhaskar, P.T.; Miller, L.; Wang, Z.; Wheaton, W.; Chandel, N.; Laakso, M.; Muller, W.J.; Allen, E.L.; et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. *Cancer Cell* 2013, 24, 213–228. [CrossRef] [PubMed]

64. Stein, M.; Lin, H.; Jeyamohan, C.; Dvorzhinski, D.; Gounder, M.; Bray, K.; Eddy, S.; Goodin, S.; White, E.; Dipaola, R.S. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. *Prostate* 2010, 70, 1388–1394. [CrossRef] [PubMed]

65. Dwarakanath, B.S.; Singh, D.; Banerji, A.K.; Sarin, R.; Venkataramana, N.K.; Jalali, R.; Vishwanath, P.N.; Mohanti, B.K.; Tripathi, R.P.; Kalia, V.K.; et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects. *J Cancer Res* 2009, 5(Suppl. 1), S21–S26. [CrossRef] [PubMed]

66. Poteet, E.; Choudhury, G.R.; Winters, A.; Li, W.; Ryou, M.G.; Liu, R.; Tang, L.; Ghoradope, A.; Wen, Y.; Yuan, F.; et al. Reversing the Warburg effect as a treatment for glioblastoma. *J. Biol. Chem.* 2013, 288, 9153–9164. [CrossRef]

67. Sajnani, K.; Islam, F.; Smith, R.A.; Gopalan, V.; Lam, A.K. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. *Biochimie* 2017, 135, 164–172. [CrossRef]

68. Ebert, D.; Haller, R.G.; Walton, M.E. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. *J. Neurosci.* 2003, 23, 5928–5935. [CrossRef]

69. Jiang, L.; Gulanski, B.I.; De Feyter, H.M.; Weinzimer, S.A.; Pittman, B.; Guidone, E.; Koretski, J.; Harman, S.; Petakis, I.L.; Krystal, J.H.; et al. Increased brain uptake and oxidation of acetate in heavy drinkers. *J. Clin. Investig.* 2013, 123, 1605–1614. [CrossRef] [PubMed]

70. Maher, E.A.; Marin-Valencia, I.; Bachoo, R.M.; Mashimo, T.; Hatanpaa, K.J.; Jindal, A.; Jeffrey, F.M.; Choi, C.; Madden, C.; et al. Metabolism of [U-13 C] glucose in human brain tumors in vivo. *NMR Biomed.* 2012, 25, 1234–1244. [CrossRef]

71. Mashimo, T.; Pichumani, K.; Vemireddy, V.; Hatanpaa, K.J.; Singh, D.K.; Sirasanagandla, S.; Nanpapaga, S.; Piccirillo, S.G.; Kovacs, Z.; Foong, C.; et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. *Cell* 2014, 159, 1603–1614. [CrossRef] [PubMed]

72. Wise, D.R.; Thompson, C.B. Glutamine addiction: A new therapeutic target in cancer. *Trends Biochem. Sci.* 2010, 35, 427–433. [CrossRef] [PubMed]

73. Faubert, B.; Li, K.Y.; Cai, L.; Hensley, C.T.; Kim, J.; Zacharias, L.G.; Yang, C.; Do, Q.N.; Doucette, S.; Burguete, D.; et al. Lactate Metabolism in Human Lung Tumors. *Cell* 2017, 171, 358–371. [CrossRef] [PubMed]

74. Hui, S.; Ghergurovich, J.M.; Morsch, R.J.; Jang, C.; Teng, X.; Lu, W.; Esparza, L.A.; Reya, T.; Le, Z.; Yanxiang Guo, J.; et al. Glucose feeds the TCA cycle via circulating lactate. *Nature* 2017, 551, 115–118. [CrossRef] [PubMed]

75. Xu, X.; Zhao, J.; Xu, Z.; Peng, B.; Huang, Q.; Arnold, E.; Ding, J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. *J. Biol. Chem.* 2004, 279, 33946–33957. [CrossRef] [PubMed]

76. Krell, D.; Assoku, M.; Galloway, M.; Mulholland, P.; Tomlinson, I.; Bardella, C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. *PLoS ONE* 2011, 6, e19868. [CrossRef] [PubMed]
77. Joseph, J.W.; Jensen, M.V.; Ilkayeva, O.; Palmieri, F.; Alarcon, C.; Rhodes, C.J.; Newgard, C.B. The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion. *J. Biol. Chem.* **2006**, *281*, 35624–35632. [CrossRef] [PubMed]

78. Metallo, C.M.; Gameiro, P.A.; Bell, E.L.; Mattaini, K.R.; Yang, J.; Hiller, K.; Jewell, C.M.; Johnson, Z.R.; Irvine, D.J.; Guarente, L.; et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature* **2011**, *481*, 380–384. [CrossRef]

79. Filipp, F.V.; Scott, D.A.; Ronai, Z.A.; Osterman, A.L.; Smith, J.W. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. *Pigment Cell Melanoma Res.* **2012**, *25*, 375–383. [CrossRef] [PubMed]

80. Lee, S.M.; Park, S.Y.; Shin, S.W.; Kil, I.S.; Yang, E.S.; Park, J.W. Silencing of cytosolic NADP (+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine. *Free Radic. Res.* **2009**, *43*, 165–173. [CrossRef]

81. Lee, S.H.; Jo, S.H.; Lee, S.M.; Koh, H.J.; Song, H.; Park, J.W.; Lee, W.H.; Huh, T.L. Role of NADP (+)-dependent isocitrate dehydrogenase (NADP+–ICDH) on cellular defence against oxidative injury by gamma-rays. *Int. J. Radiat. Biol.* **2004**, *80*, 635–642. [CrossRef] [PubMed]

82. Wahl, D.R.; Dresser, J.; Wilder-Romans, K.; Parsels, J.D.; Zhao, S.G.; Davis, M.; Zhao, L.; Kachman, M.; Wernisch, S.; Burant, C.F.; et al. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. *Cancer Res.* **2017**, *77*, 960–970. [CrossRef] [PubMed]

83. Calvert, A.E.; Chalastanis, A.; Wu, Y.; Hurley, L.A.; Kouri, F.M.; Bi, Y.; Kachman, M.; May, J.L.; Bartom, E.; Joseph, J.W.; Jensen, M.V.; Ilkayeva, O.; Palmieri, F.; Alarcon, C.; Rhodes, C.J.; Newgard, C.B. The role of NADP(+)-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays. *Int. J. Radiat. Biol.* **2004**, *80*, 635–642. [CrossRef] [PubMed]

84. Altman, B.J.; Stine, Z.E.; Dang, C.V. From Krebs to clinic: Glutamine metabolism to cancer therapy. *Annu. Rev. Nutr.* **2019**, *39*, 133–159. [CrossRef] [PubMed]

85. Tanaka, K.; Sasayama, T.; Irino, Y.; Takata, K.; Nagashima, H.; Satoh, N.; Kyotani, K.; Mizowaki, T.; Imahori, T.; Ejima, Y.; et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. *J. Clin. Investig.* **2015**, *125*, 1591–1602. [CrossRef] [PubMed]

86. Bagga, P.; Behar, K.L.; Mason, G.F.; De Feyter, H.M.; Rothman, D.L.; Patel, A.B. Characterization of cerebral glutamine uptake from blood in the mouse brain: Implications for metabolic modeling of 13C NMR data. *J. Cereb. Blood Flow Metab.* **2014**, *34*, 1666–1672. [CrossRef] [PubMed]

87. Martinez-Hernandez, A.; Bell, K.; Norenberg, M. Glutamine synthetase: Glial localization in brain. *Science* **1977**, *195*, 1356–1358. [CrossRef] [PubMed]

88. Rosati, A.; Poliani, P.L.; Todeschini, A.; Cominelli, M.; Medicina, D.; Cenzo, M.; Simoncini, E.L.; Magrini, S.M.; Buglione, M.; Grisanti, S.; et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. *Neuro Oncol.* **2013**, *15*, 618–625. [CrossRef] [PubMed]

89. Tardito, S.; Oudin, A.; Ahmed, S.U.; Fack, F.; Keunen, O.; Zheng, L.; Miletic, H.; Sakariassen, P.O.; Weinstock, A.; Wagner, A.; et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. *Nat. Cell Biol.* **2015**, *17*, 1556–1568. [CrossRef]

90. Curthoys, N.P.; Watford, M. Regulation of glutaminase activity and glutamine metabolism. *Annu. Rev. Nutr.* **1995**, *15*, 133–159. [CrossRef]

91. Cheng, T.; Sudderth, J.; Yang, C.; Mullen, A.R.; Jin, E.S.; Mates, J.M.; DeBerardinis, R.J. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 8674–8679. [CrossRef] [PubMed]

92. Oizel, K.; Chauvin, C.; Oliver, L.; Gratas, C.; Geraldo, F.; Jarry, U.; Scotet, E.; Rabe, M.; Alves-Guerra, M.C.; Teusan, R.; et al. Efficient Mitochondrial Glutamine Targeting Prevalts Over Glioblastoma Metabolic Plasticity. *Clin. Cancer Res.* **2017**, *23*, 6292–6304. [CrossRef] [PubMed]

93. Seltzer, M.J.; Bennett, B.D.; Joshi, A.D.; Gao, P.; Thomas, A.G.; Ferraris, D.V.; Tsukamoto, T.; Rojas, C.J.; Slusher, B.S.; Rabinowitz, J.D.; et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer Res.* **2010**, *70*, 8981–8987. [CrossRef] [PubMed]

94. Wise, D.R.; DeBerardinis, R.J.; Mancuso, A.; Sayed, N.; Zhang, X.Y.; Pfeiffer, H.K.; Nissim, I.; Daikhin, E.; Yudkoff, M.; McMahon, S.B.; et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 18782–18787. [CrossRef] [PubMed]
95. O’Brien, J.S.; Sampson, E.L. Lipid composition of the normal human brain: Gray matter, white matter, and myelin. *J. Lipid Res.* 1965, 6, 537–544. [PubMed]

96. Guo, D.; Bell, E.H.; Chakravarti, A. Lipid metabolism emerges as a promising target for malignant glioma therapy. *CNS Oncol.* 2013, 2, 289–299. [CrossRef] [PubMed]

97. Santos, C.R.; Schulze, A. Lipid metabolism in cancer. *FEBS J.* 2012, 279, 2610–2623. [CrossRef] [PubMed]

98. Jones, J.E.; Esler, W.P.; Patel, R.; Lanba, A.; Vera, N.B.; Pfefferkorn, J.A.; Vernochet, C. Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRLIII Human Glioblastoma Cells. *PLoS ONE* 2017, 12, e0169566. [CrossRef] [PubMed]

99. Guo, D.; Hildebrandt, I.J.; Prins, R.M.; Soto, H.; Mazzotta, M.M.; Dang, J.; Czernin, J.; Shyy, J.Y.; Watson, A.D.; Phelps, M.; et al. The AMPK agonist AICAR inhibits the growth of EGFRLIII-expressing glioblastomas by inhibiting lipogenesis. *Proc. Natl. Acad. Sci. USA* 2009, 106, 12932–12937. [CrossRef]

100. Guo, D.; Prins, R.M.; Dang, J.; Kuga, D.; Iwanami, A.; Soto, H.; Lin, K.Y.; Huang, T.T.; Akhavan, D.; Barbachyn, A.; et al. Lipid metabolism in cancer. *FEBS J.*

101. Santos, C.R.; Schulze, A. Lipid metabolism in cancer. *FEBS J.* 2012, 279, 2610–2623. [CrossRef] [PubMed]

102. Guo, D.; Reinitz, F.; Youssef, M.; Hong, C.; Nathanson, D.; Akhavan, D.; Kuga, D.; Amzajerdi, A.N.; Soto, H.; Zhu, S.; et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. *Cancer Discov.* 2011, 1, 442–456. [CrossRef] [PubMed]

103. Altwairgi, A.K.; Alghareeb, W.; Alnajjar, F.; Alsaeed, E.; Balbaid, A.; Alhussain, H.; Aldanan, S.; Orz, Y.; Lari, A.; Alsharm, A. Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Interim analysis report. *PLoS ONE* 2012, 7, e52113. [CrossRef] [PubMed]

104. Cheng, C.; Ru, P.; Geng, F.; Liu, J.; Yoo, J.Y.; Wu, X.; Cheng, X.; Euthine, V.; Hu, P.; Guo, J.Y.; et al. Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. *Cancer Cell* 2015, 28, 569–581. [CrossRef] [PubMed]

105. Ru, P.; Hu, P.; Geng, F.; Mo, X.; Cheng, C.; Yoo, J.Y.; Cheng, X.; Wu, X.; Guo, J.Y.; Nakano, I.; et al. Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. *Cell Rep.* 2016, 16, 1527–1535. [CrossRef] [PubMed]

106. Geng, F.; Cheng, X.; Wu, X.; Yoo, J.Y.; Cheng, C.; Guo, J.Y.; Mo, X.; Ru, P.; Hurwitz, B.; Kim, S.H.; et al. Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis. *Clin. Cancer Res.* 2016, 22, 5337–5348. [CrossRef]

107. Luo, L.; Yang, W.; Zhang, X.; Xue, Q.; Xie, L.; et al. Enhancing the effects of a dietary intervention on adipocyte function and bodyweight: A systematic review and meta-analysis of randomized controlled trials. *Nutrients* 2016, 8, 171. [CrossRef] [PubMed]

108. Guo, D.; Reinitz, F.; Youssef, M.; Hong, C.; Nathanson, D.; Akhavan, D.; Kuga, D.; Amzajerdi, A.N.; Soto, H.; Zhu, S.; et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. *Cancer Discov.* 2011, 1, 442–456. [CrossRef] [PubMed]

109. Lu, V.M.; McDonald, K.L. The current evidence of statin use affecting glioblastoma prognosis. *J. Clin. Neurosci.* 2017, 42, 196–197. [CrossRef] [PubMed]
115. Jiang, P.; Mukthavaram, R.; Chao, Y.; Bharati, I.S.; Fogal, V.; Pastorino, S.; Cong, X.; Nomura, N.; Gallagher, M.; Abbasi, T.; et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. *J. Transl. Med.* 2014, 12, 13. [CrossRef] [PubMed]

116. Wang, X.; Yang, K.; Xie, Q.; Wu, Q.; Mack, S.C.; Shi, Y.; Kim, J.Y.J.; Prager, B.C.; Flavahan, W.A.; Liu, X.; et al. Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. *Nat. Neurosci.* 2017, 20, 661–673. [CrossRef] [PubMed]

117. Laks, D.R.; Ta, L.; Crisman, T.J.; Gao, F.; Coppola, G.; Radu, C.G.; Nathanson, D.A.; Kornblum, H.I. Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma. *Mol. Cancer Ther.* 2016, 15, 1271–1278. [CrossRef] [PubMed]

118. Nikaki, A.; Angelidis, G.; Efthimiadou, R.; Tsougos, I.; Valotassiou, V.; Fountas, K.; Prasopoulos, V.; Georgoulas, P. (18) F-fluorothymidine PET imaging in gliomas: An update. *Ann. Nucl. Med.* 2017, 31, 495–505. [CrossRef]

119. Spector, R. Hypoxanthine transport and metabolism in the central nervous system. *J. Neurochem.* 1988, 50, 969-978. [CrossRef] [PubMed]

120. Apparaju, S.K.; Gudelsky, G.A.; Desai, P.B. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: An in vivo assessment in rats employing intracerebral microdialysis. *Cancer Chemother. Pharmacol.* 2008, 61, 223–229. [CrossRef]

121. Sigmond, J.; Honeywell, R.J.; Postma, T.J.; Dirven, C.M.; de Lange, S.M.; van der Born, K.; Laan, A.C.; Baayen, J.C.; Van Groeningen, C.J.; Bergman, A.M.; et al. Gemcitabine uptake in glioblastoma multiforme: Potential as a radiosensitizer. *Ann. Oncol.* 2009, 20, 182–187. [CrossRef] [PubMed]

122. Bastiancich, C.; Bastiat, G.; Lagarce, F. Gemcitabine and glioblastoma: Challenges and current perspectives. *Drug Discov. Today* 2018, 23, 416–423. [CrossRef] [PubMed]

123. Kim, D.; Fiske, B.P.; Birsoy, K.; Freinkman, E.; Kami, K.; Possemato, R.L.; Chudnovsky, Y.; Pacold, M.E.; Chen, W.W.; Cantor, J.R.; et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. *Nature* 2015, 520, 363–367. [CrossRef] [PubMed]

124. Celami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The eBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012, 2, 401–404. [CrossRef]

125. Marjon, K.; Cameron, M.J.; Quang, P.; Clasquin, M.F.; Mandley, E.; Kunii, K.; McVay, M.; Choe, S.; Kernytsky, A.; Gross, S.; et al. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. *Cell Rep.* 2016, 15, 574–587. [CrossRef]

126. Kryukov, G.V.; Wilson, F.H.; Ruth, J.R.; Pauluk, J.; Tsherniak, A.; Marlow, S.E.; Vazquez, F.; Weir, B.A.; Fitzgerald, M.E.; Tanaka, M.; et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. *Science* 2016, 351, 1214–1218. [CrossRef] [PubMed]

127. Mavrakis, K.J.; McDonald, E.R.; Schlabach, M.R.; Birsoy, K.; Freinkman, E.; Kami, K.; Possemato, R.L.; Chudnovsky, Y.; Pacold, M.E.; Chen, W.W.; Cantor, J.R.; et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. *Nature* 2015, 520, 363–367. [CrossRef] [PubMed]

128. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The eBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012, 2, 401–404. [CrossRef] [PubMed]

129. Marjon, K.; Cameron, M.J.; Quang, P.; Clasquin, M.F.; Mandley, E.; Kunii, K.; McVay, M.; Choe, S.; Kernytsky, A.; Gross, S.; et al. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. *Cell Rep.* 2016, 15, 574–587. [CrossRef]

130. Gao, X.; Sanderson, S.M.; Dai, Z.; Reid, M.A.; Cooper, D.E.; Lu, M.; Michel, P.G.; et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism. *Nature* 2019, 572, 397–401. [CrossRef]

131. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008, 321, 1807–1812. [CrossRef] [PubMed]

132. Hartmann, C.; Meyer, J.; Baliss, J.; Capper, D.; Mueller, W.; Christians, A.; Felsberg, J.; Wolter, M.; Mawrin, C.; Wick, W.; et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendrogial differentiation and age: A study of 1,010 diffuse gliomas. *Acta Neuropathol.* 2009, 118, 469–474. [CrossRef] [PubMed]
133. Lai, A.; Kharbanda, S.; Pope, W.B.; Tran, A.; Solis, O.E.; Peale, F.; Forrest, W.F.; Pujara, K.; Carrillo, J.A.; Pandita, A.; et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 2011, 29, 4482–4490. [CrossRef] [PubMed]

134. Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324, 261–265. [CrossRef] [PubMed]

135. Jin, G.; Reitman, Z.J.; Duncan, C.G.; Spasojevic, I.; Gooden, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739–744. [CrossRef] [PubMed]

136. Ward, P.S.; Lu, C.; Cross, J.R.; Abdel-Wahab, O.; Levine, R.L.; Schwartz, G.K.; Thompson, C.B. The potential of isocitrate dehydrogenase as a target for tumor-specific metabolic targeting. J. Biol. Chem. 2017, 292, 7971–7983. [CrossRef] [PubMed]

137. Avellaneda Matteo, D.; Grunseth, A.J.; Gonzalez, E.R.; Anselmo, S.L.; Kennedy, M.A.; Moman, P.; Scott, D.A.; Hoang, A.; Sohl, C.D. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency. J. Biol. Chem. 2017, 288, 3804–3815. [CrossRef] [PubMed]

138. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.T.; et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19, 17–30. [CrossRef] [PubMed]

139. Dang, L.; White, D.W.; Gross, S.; Bennettt, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. J. Biol. Chem. 2018, 293, 20051–20061. [CrossRef] [PubMed]

140. Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohde, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A.; et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474–478. [CrossRef]

141. Izquierdo-Garcia, J.L.; Viswanath, P.; Eriksson, P.; Cai, L.; Radoul, M.; Chaumeil, M.M.; Blough, M.; Mellingho, I.K.; Touat, M.; Maher, E.; De la Fuente, M.; Cloughesy, T.F.; Holdhoff, M.; Cote, G.M.; Burris, H.; Janku, F.; Huang, R.; et al. Ag-120, a First-in-Class Mutant Idh1 Inhibitor in Patients with Recurrent or Progressive Idh1 Mutant Glioma: Updated Results from the Phase 1 Non-Enhancing Glioma Population. Cancer Res. 2017, 77, 22 of 26. [CrossRef] [PubMed]

142. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.T.; et al. Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep. 2018, 23, 1553–1564. [CrossRef] [PubMed]

143. Rohde, D.; Popovici-Muller, J.; Palaska, N.; Turcan, S.; Grommes, C.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.; Komisopoulou, E.; et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340, 626–630. [CrossRef] [PubMed]

144. Dang, L.; White, D.W.; Gross, S.; Bennettt, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739–744. [CrossRef] [PubMed]

145. Jin, G.; Reitman, Z.J.; Duncan, C.G.; Spasojevic, I.; Gooden, D.M.; Rasheed, B.A.; Yang, R.; Lopez, G.Y.; He, Y.; McDendon, R.E.; et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res. 2013, 73, 496–501. [CrossRef] [PubMed]
150. Fu, X.; Chin, R.M.; Vergnes, L.; Hwang, H.; Deng, G.; Xing, Y.; Pai, M.Y.; Li, S.; Ta, L.; Fazlollahi, F.; et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. *Cell Metab.* 2015, 22, 508–515. [CrossRef]  

151. McBrayer, S.K.; Mayers, J.R.; DiNatale, G.J.; Shi, D.D.; Khanal, J.; Chakraborty, A.A.; Sarosiek, K.A.; Briggs, K.J.; Robbins, A.K.; Sewastianik, T.; et al. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. *Cell* 2018, 175, 101–116. [CrossRef]  

152. Lu, Y.; Kwintkiewicz, J.; Liu, Y.; Tech, K.; Frady, L.N.; Su, Y.T.; Bautista, W.; Moon, S.I.; MacDonald, J.;  

153. Sulkowski, P.L.; Corso, C.D.; Scanlon, S.E.; Purshouse, K.R.; Bai, H.; Liu, Y.; Sundaram, R.K.;  

154. Molenaar, R.J.; Botman, D.; Smits, M.A.; Hira, V.V.; et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. *Cell Res.* 2015, 75, 4790–4802. [CrossRef] [PubMed]  

155. Nunez, F.J.; Mendez, F.M.; Kadiyala, P.; Alghamri, M.S.; Savelieff, M.G.; Garcia-Fabiani, M.B.; Haase, S.; Koschromm, C.; Calinescu, A.A.; Kamran, N.; et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. *Sci. Transl. Med.* 2019, 11, eaav427. [CrossRef] [PubMed]  

156. Johannesssen, T.A.; Mukherjee, J.; Viswanath, P.; Ohba, S.; Ronen, S.M.; Bjerkvig, R.; Pieper, R.O. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. *Mol. Cancer Res. MCR* 2016, 14, 976–983. [CrossRef] [PubMed]  

157. Tateishi, K.; Wakimoto, H.; IafRATE, A.J.; Tanaka, S.; Loebel, F.; Lelic, N.; Wiederschain, D.; Bedel, O.; Deng, G.; Zhang, B.;  

158. Vartanian, A.; Agnihotri, S.; Wilson, M.R.; Burrell, K.E.; Tonge, P.D.; Alamsahebpour, A.; Jalali, S.; Taccone, M.S.; Mansouri, S.; Gelbourn, B.; et al. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. *Oncotarget* 2016, 7, 69518–69535. [CrossRef] [PubMed]  

159. Stacpoole, P.W. The pharmacology of dichloroacetate. *Metab. Clin. Exp.* 1989, 38, 1124–1144. [CrossRef]  

160. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; et al. A mitochondria-K<sup>+</sup> channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. *Cancer Cell* 2007, 11, 37–51. [CrossRef]  

161. Shen, H.; Hau, E.; Joshi, S.; Dilda, P.J.; McDonald, K.L. Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism. *Mol. Cancer Ther.* 2015, 14, 1794–1804. [CrossRef]  

162. Michelakis, E.D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T.L.; Mackey, J.R.; Fulton, D.; et al. Metabolic modulation of glioblastoma with dichloroacetate. *Sci. Transl. Med.* 2010, 2, 31ra34. [CrossRef] [PubMed]  

163. Almeida, K.H.; Sobol, R.W. A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification. *DNA Repair* 2007, 6, 695–711. [CrossRef] [PubMed]  

164. Sims, J.L.; Berger, S.J.; Berger, N.A. Effects of nicotinamide on NAD and poly(ADP-ribose) metabolism in DNA-damaged human lymphocytes. *J. Supramol. Struct. Cell. Biochem.* 1981, 16, 281–288. [CrossRef] [PubMed]  

165. Hassa, P.O.; Haenni, S.S.; Elser, M.; Hottiger, M.O. Nuclear ADP-ribosylation reactions in mammalian cells: Where are we today and where are we going? *Microbiol. Mol. Biol. Rev. MMBR* 2006, 70, 789–829. [CrossRef] [PubMed]  

166. Barazzuol, L.; Jena, R.; Burnet, N.G.; Meira, L.B.; Jeynes, J.C.; Kirkby, K.J.; Kirkby, N.F. Evaluation of poly(ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. *Radiat. Oncol.* 2013, 8, 65. [CrossRef] [PubMed]  

167. Dungey, F.A.; Loser, D.A.; Chalmers, A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: Mechanisms and therapeutic potential. *Int. J. Radiat. Oncol. Biol. Phys.* 2008, 72, 1188–1197. [CrossRef] [PubMed]
168. Russo, A.L.; Kwon, H.C.; Burgan, W.E.; Carter, D.; Beam, K.; Weizheng, X.; Zhang, J.; Slusher, B.S.; Chakravarti, A.; Tofilon, P.J.; et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly(ADP-ribose) polymerase inhibitor E7016. Clin. Cancer Res. 2009, 15, 607–612. [CrossRef]

169. Gujar, A.D.; Le, S.; Mao, D.D.; Daday, D.Y.; Turski, A.; Sasaki, Y.; Aum, D.; Luo, J.; Dahiy, S.; Yuan, L.; et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc. Natl. Acad. Sci. USA 2016, 113, E8247–E8256. [CrossRef]

170. Sampath, D.; Zabka, T.S.; Misner, D.L.; O’Brien, T.; Dragovich, P.S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol. Ther. 2015, 151, 16–31. [CrossRef]

171. Ma, Y.; Chapman, J.; Levine, M.; Polireddy, K.; Drisko, J.; Chen, Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl. Med. 2014, 6, 222ra218. [CrossRef]

172. Du, J.; Martin, S.M.; Levine, M.; Wagner, B.A.; Buettner, G.R.; Wang, S.H.; Taghiyev, A.F.; Du, C.; Knudson, C.M.; Cullen, J.J. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res. 2010, 16, 509–520. [CrossRef] [PubMed]

173. Yun, J.; Mullarky, E.; Lu, C.; Bosch, K.N.; Kavalier, A.; Rivera, K.; Roper, J.; Chio, I.I.; Giannopoulou, E.G.; Rago, C.; et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015, 350, 1391–1396. [CrossRef] [PubMed]

174. Castro, M.L.; Carson, G.M.; McConnell, M.J.; Herst, P.M. High Dose Ascorbate Causes Both Genotoxic and Metabolic Stress in Glioma Cells. Antioxidants 2017, 6. [CrossRef] [PubMed]

175. Schoenfeld, J.D.; Sibenaller, Z.A.; Mapuskar, K.A.; Wagner, B.A.; Cramer-Morales, K.L.; Furqan, M.; Sandhu, S.; Carlisle, T.L.; Smith, M.C.; Abu Hejleh, T.; et al. O2(-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 2017, 32, 268. [CrossRef] [PubMed]

176. Daye, D.; Wellen, K.E. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 2012, 23, 362–369. [CrossRef] [PubMed]

177. Kim, M.M.; Camelo-Piragua, S.; Schipper, M.; Tao, Y.; Normolle, D.; Junck, L.; Mammoser, A.; Betz, B.L.; Cao, Y.; Kim, C.J.; et al. Gencitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study. Int. J. Radiat. Oncol. Biol. Phys. 2016, 94, 305–311. [CrossRef]

178. Chong, D.Q.; Toh, X.Y.; Ho, I.A.; Sia, K.C.; Newman, J.P.; Yulyana, Y.; Ng, W.H.; Lai, S.H.; Ho, M.M.; Dinesh, N.; et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer 2015, 15, 255. [CrossRef]

179. Velpula, K.K.; Guda, M.R.; Sahu, K.; Tuszynski, J.; Asuthkar, S.; Bach, S.E.; Lathia, J.D.; Tsung, A.J. Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. Oncotarget 2017, 8, 35639–35655. [CrossRef] [PubMed]
185. Mazor, G.; Levin, L.; Picard, D.; Ahmadov, U.; Caren, H.; Borkhardt, A.; Reifenberger, G.; Leprivier, G.; Remke, M.; Rotblat, B. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. *Cell Death Dis.* 2019, 10, 246. [CrossRef] [PubMed]

186. Huang, J.; DeWees, T.; Campian, J.L.; Chheda, M.G.; Anstas, G.; Tsien, C.; Zipfel, G.J.; Dunn, G.P.; Ippolito, J.E.; Cairncross, J.G.; et al. A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma. *J. Clin. Oncol.* 2019, 37, 2033. [CrossRef] [PubMed]

187. Kang, M.K.; Kang, S.K. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. *Stem Cells Dev.* 2007, 16, 837–847. [CrossRef]

188. Xu, R.H.; Pelicano, H.; Zhang, H.; Giles, F.J.; Keating, M.J.; Huang, P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. *Leukemia* 2005, 19, 2153–2158. [CrossRef]

189. Yuan, S.; Wang, F.; Chen, G.; Zhang, H.; Feng, L.; Wang, L.; Colman, H.; Keating, M.J.; Li, X.; Xu, R.H.; et al. Effective elimination of cancer stem cells by a novel drug combination strategy. *Stem Cells* 2013, 31, 23–34. [CrossRef]

190. Zhou, Y.; Zhou, Y.; Shingu, T.; Feng, L.; Chen, Z.; Ogasawara, M.; Keating, M.J.; Kondo, S.; Huang, P. Metabolic alterations in highly tumorigenic glioblastoma cells: Preference for hypoxia and high dependency on glycolysis. *J. Biol. Chem.* 2011, 286, 32843–32853. [CrossRef]

191. Chang, S.M.; Wen, P.; Cloughesy, T.; Greenberg, H.; Schiff, D.; Conrad, C.; Fink, K.; Robins, H.J.; De Angelis, L.; Raizer, J.; et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. *Investig. New Drugs* 2005, 23, 357–361. [CrossRef]
202. Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme. Available online: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did (accessed on 7 August 2019).

203. Cloughesey, T.F.; Mochizuki, A.Y.; Orpilla, J.R.; Hugo, W.; Lee, A.H.; Davidson, T.B.; Wang, A.C.; Ellingson, B.M.; Rytlewski, J.A.; Sanders, C.M.; et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 2019, 25, 477–486. [CrossRef] [PubMed]

204. McGranahan, T.; Therkelsen, K.E.; Ahmad, S.; Nagpal, S. Current State of Immunotherapy for Treatment of Glioblastoma. Curr. Treat. Options Oncol. 2019, 20, 24. [CrossRef] [PubMed]

205. Fischer, K.; Hoffmann, P.; Voelkl, S.; Meidenbauer, N.; Ammer, J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109, 3812–3819. [CrossRef] [PubMed]

206. Zhang, W.; Wang, G.; Xu, Z.G.; Tu, H.; Hu, F.; Dai, J.; Chang, Y.; Chen, Y.; Lu, Y.; Zeng, H.; et al. Lactate is a natural suppressor of RLR signaling by targeting MAVS. Cell 2019, 178, 176–189. [CrossRef] [PubMed]

207. Doherty, J.R.; Cleveland, J.L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Investig. 2013, 123, 3685–3692. [CrossRef] [PubMed]

208. Romero-Garcia, S.; Moreno-Altimirano, M.M.; Prado-Garcia, H.; Sanchez-Garcia, F.J. Lactate contribution to the tumor microenvironment: Mechanisms, Effects on immune cells and Therapeutic Relevance. Front. Immunol. 2016, 7, 52. [CrossRef]

209. Zhai, L.; Lauing, K.L.; Chang, A.L.; Dey, M.; Qian, J.; Cheng, Y.; Lesniak, M.S.; Wainwright, D.A. The role of IDO in brain tumor immunotherapy. J. Neuro Oncol. 2015, 123, 395–403. [CrossRef]

210. Wainwright, D.A.; Chang, A.L.; Dey, M.; Balyasnikova, I.V.; Kim, C.K.; Tobias, A.; Cheng, Y.; Kim, J.W.; Qiao, J.; Zhang, L.; et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 2014, 20, 5290–5301. [CrossRef]

211. Aoki, K.; Nakamura, H.; Suzuki, H.; Matsuo, K.; Kataoka, K.; Shimamura, T.; Motomura, K.; Ohka, F.; Shiina, S.; Yamamoto, T.; et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018, 20, 66–77. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).